Nephrolithiasis

On this page

Quick Reference

RxDrug of choiceKetorolac (acute pain), Tamsulosin (expulsive therapy), Potassium Citrate (prevention)

AltAlternativesAcetaminophen/Oxycodone (pain), Thiazides (hypercalciuria), Allopurinol (uric acid stones)

⊘AvoidNon-dihydropyridine CCBs (in HF), NSAIDs (in CKD or pregnancy), SWL (in pregnancy or distal obstruction)

DxTest of choiceNon-contrast CT (NCCT) of the abdomen and pelvis

ScKey scoreCLAD-MB score (predicts need for urgent surgery)

→When to referObstructed infected system, solitary kidney obstruction, stones >10 mm, or failed medical management

Nephrolithiasis is a metabolic disease requiring acute surgical or medical clearance followed by aggressive fluid and dietary modification to prevent high recurrence rates.

Nephrolithiasis, the formation of solid mineral deposits within the renal parenchyma or collecting system, is a systemic metabolic disorder with a rising global prevalence of 7% to 13%. While often asymptomatic, stones can cause excruciating renal colic, hematuria, and life-threatening urosepsis if obstruction occurs. Management has shifted from invasive open surgery to a paradigm of minimally invasive endourology, including [[ureteroscopy]] (URS), [[percutaneous nephrolithotomy]] (PCNL), and [[shock wave lithotripsy]] (SWL). Beyond surgical clearance, long-term care requires metabolic risk stratification via 24-hour urine analysis to prevent a 50% recurrence rate within five years. Key drivers include metabolic syndrome, dehydration, and dietary imbalances, making high fluid intake (target >2.5 L/day urine output) the cornerstone of secondary prevention.

Overview and Recommendations

Background

•Nephrolithiasis, the presence of renal calculi, affects approximately 1 in 11 people in the U.S., with a narrowing gender gap and a strong association with metabolic syndrome, obesity, and cardiovascular disease.
•Calcium oxalate (CaOx) is the most common composition (~75%), often originating as attached deposits on (interstitial hydroxyapatite) before eroding into the collecting system.
•The physicochemical cascade involves urinary supersaturation, crystal nucleation (promoted by proteins like CD44), and aggregation, which is further exacerbated by oxidative stress and mitochondrial dysfunction in renal tubular cells.
•Secondary etiologies must be ruled out, including , malabsorptive states (e.g., , bariatric surgery), and genetic defects like or distal renal tubular acidosis.
•Prognostic stakes are high; untreated obstructive stones can lead to permanent renal function decline, while infected obstruction carries a 20% mortality rate if septic multi-organ failure develops.

Evaluation

•Suspect nephrolithiasis in patients presenting with acute, paroxysmal unilateral flank pain radiating to the groin, often accompanied by nausea, vomiting, and microscopic or macroscopic hematuria.
•Ask about personal or family history of stones, dietary habits (low fluid, high sodium), and history of UTIs or malabsorptive gastrointestinal disorders.
•Examine for costovertebral angle (CVA) tenderness and assess for systemic signs of infection, such as fever, hypotension, or tachycardia, which indicate a urological emergency.
•Order non-contrast computed tomography (NCCT) as the gold-standard diagnostic tool for adults to determine stone size, location, and density (Hounsfield Units).
•Utilize as the first-line imaging modality in children and pregnant patients to minimize ionizing radiation, though it may underestimate stone size or miss stones <5 mm.
•Assess renal function with serum creatinine and obtain a urinalysis to check for pH (low pH <5.5 suggests uric acid; high pH >7.2 suggests struvite) and signs of infection.
•Perform a 24-hour urine collection in recurrent or high-risk formers to measure calcium, oxalate, citrate, sodium, and uric acid levels for metabolic profiling.
•Identify 'urgent' stones requiring immediate intervention: obstructing stones with concomitant infection, stones in a solitary kidney, or intractable pain/vomiting.

Management

•Decompress the collecting system immediately via or (PCN) in any patient with an obstructed, infected kidney or calculous anuria.
•Administer (e.g., 30 mg IV or 600 mg) as first-line analgesia for acute renal colic; they are superior to opioids for reducing ED returns.
•Initiate Medical Expulsive Therapy (MET) with 0.4 mg daily for distal ureteral stones 4-10 mm to facilitate spontaneous passage.
•Select (URS) with laser lithotripsy for most symptomatic renal stones <20 mm, especially those in the lower pole where stone displacement to the upper pole improves clearance.
•Perform (PCNL) for large stone burdens (>20 mm) or complex staghorn calculi to achieve the highest stone-free rates (SFR).
•Utilize (SWL) for small (<10 mm), non-lower pole, radiopaque stones in patients who prefer a non-invasive approach.
•Prescribe high fluid intake to achieve a target urine output of >2.5 L/day, which reduces the risk of recurrence by approximately 40%.
•Administer (e.g., 20-30 mEq BID or TID) for patients with hypocitraturia or uric acid stones to alkalinize the urine and inhibit crystal growth.
•Consider diuretics (e.g., 25-50 mg daily) for recurrent calcium stone formers with hypercalciuria, though monitoring for hypokalemia and new-onset diabetes is required.
•Avoid routine use of unless managing refractory struvite stones due to a high side-effect profile, including tremulousness and phlebothrombosis.

Board Review — High Yield

•Randall's Plaque, Subepithelial calcium phosphate deposits on the renal papilla that serve as a nidus for calcium oxalate stones.
•Struvite Stones, Composed of magnesium ammonium phosphate; associated with urease-producing bacteria (Proteus, Klebsiella) and high urinary pH.
•Uric Acid Stones, Radiolucent on X-ray but visible on CT; can often be dissolved with oral chemolysis (alkalinization to pH 6.5-7.0).
•Cystinuria, Hexagonal crystals on microscopy; caused by a defect in the COAL transporter (Cystine, Ornithine, Arginine, Lysine).
•Indinavir Stones, One of the few stone types that may be radiolucent even on non-contrast CT.
•Shock Wave Lithotripsy (SWL) Contraindications, Pregnancy, uncorrected coagulopathy, distal obstruction, and aortic/renal artery aneurysms.
•Thiazide Mechanism, Reduces urinary calcium by increasing proximal and distal convoluted tubule calcium reabsorption.
•Hypocitraturia, Citrate is a potent inhibitor of calcium stone formation; levels are often low in chronic metabolic acidosis or distal RTA.

Deep Dive — Evidence Details

Definition, Classification & Nomenclature

▸Nephrolithiasis refers specifically to calculi within the kidney, while urolithiasis covers the entire urinary tract.
▸Stones are classified by mineral composition (e.g., calcium oxalate, uric acid) and surgical complexity using the Satava and Clavien systems.
▸Idiopathic calcium nephrolithiasis is a diagnosis of exclusion requiring the absence of systemic metabolic disorders.

HY High Yield: The Stone-Free Rate (SFR) is the primary endpoint for surgical success; in specialized protocols, SFR can reach 100% for 10-20 mm calculi [6].

Kidney stone disease or urinary stone disease is a crystallopathy that occurs when there is an excess of minerals in the urine and not enough liquid or hydration. This imbalance causes tiny crystals to aggregate and form — Kidney stone disease — Kidney stone disease or urinary stone disease is a crystallopathy that occurs when there is an excess of minerals in the urine and not enough liquid o...Wikipedia ↗

Nephrolithiasis is a urological condition characterized by the formation of solid mineral deposits, or calculi, within the renal parenchyma or collecting system. While often used interchangeably with urolithiasis, nephrolithiasis specifically refers to stones originating in the kidney, whereas urolithiasis encompasses stones located anywhere in the urinary tract, including the ureters and bladder ^[1]^A1c^[8]^D5.

Synonyms and Abbreviations

Nephrolithiasis: Kidney stones, renal calculi
Urolithiasis: Urinary tract stones
RIRS: Retrograde intrarenal surgery
URS: Ureteroscopy
PCNL: Percutaneous nephrolithiasis

Classification Systems

Urologists classify stones based on anatomical location, mineral composition, and surgical complexity. Clinical is frequently guided by the stone's position within the kidney (e.g., lower pole, renal pelvis) and its size, typically measured in millimeters ^[6]^C4.

Classification Axis	Categories / Variants	Clinical Significance
Composition	Calcium oxalate, Calcium phosphate, Uric acid, Struvite, Cystine	Dictates metabolic workup and medical prevention strategies ^[1]^A1c.
Etiology	Idiopathic calcium nephrolithiasis vs. Secondary forms	Secondary forms are associated with systemic disorders or specific metabolic defects ^[1]^A1c.
Surgical Complexity	Satava Classification (Grades 1-3)	Used to categorize intraoperative complications during endoscopic procedures ^[6]^C4.
Postoperative Outcomes	Clavien Classification (Grades 1-5)	Standardized system for reporting surgical complications after interventions like pyeloplasty ^[4]^C4.

Clinical Significance and Terminology

Idiopathic calcium nephrolithiasis is defined as the occurrence of calcium stones in patients without a systemic cause such as or sarcoidosis ^[1]^A1c. The condition is increasingly viewed as a systemic disorder rather than an isolated renal event, often requiring collaborative management between urologists and nephrologists ^[1]^A1c. Modern diagnostic terminology now incorporates advanced imaging and artificial intelligence (AI) for detection and segmentation, improving the accuracy of stone classification compared to traditional ultrasound ^[2]^D5.

Technological advancements have introduced specific procedural nomenclature, such as Retrograde Intrarenal Surgery (RIRS), which utilizes flexible ureteroscopy to treat renal calculi ^[6]^C4. Surgical success is primarily defined by the Stone-Free Rate (SFR), a critical metric for evaluating the efficacy of endoscopic interventions ^[6]^C4.

Pearl: Nephrolithiasis should be managed as a systemic metabolic disease rather than an isolated surgical event, necessitating a multidisciplinary approach to prevent recurrence ^[1]^A1c.

Standardized Complication and Complexity Scales

Scale	Application	Grades/Levels
Satava	Intraoperative endoscopic complications	Grades 1 to 3 ^[6]^C4
Clavien	Postoperative surgical complications	Grades 1 to 5 ^[4]^C4
DISCERN	Quality of patient education resources	1 to 5 (Quality threshold >3) ^[3]^C4

Pathophysiology & Mechanism

▸Stone formation is driven by the activation of the NLRP3 inflammasome and oxidative stress via the PKCα/NADPH oxidase pathway.
▸Most idiopathic calcium oxalate stones originate as attached deposits on interstitial Randall's plaques before detaching into the collecting system.
▸Intrarenal pressure during obstruction or intervention can reach 174 mmHg, contributing to tubular damage and potential urosepsis.

HY High Yield: Randall's plaques are hydroxyapatite (calcium phosphate) deposits in the renal papilla that serve as the anchor for the subsequent growth of calcium oxalate stones [22].

Building upon the classification of stone types, the formation of nephrolithiasis is a complex process driven by the interplay of urinary supersaturation, crystal nucleation, and the failure of endogenous inhibitory mechanisms ^[23]^D5. This transformation from dissolved solutes to solid calculi occurs through a sequence of molecular and cellular events that culminate in tissue inflammation and potential renal impairment ^[17]^D5^[21]^C4.

The Physicochemical Cascade

The transition from a clear solution to a clinical stone follows a defined mechanistic chain:

Supersaturation: High concentrations of lithogenic solutes (e.g., calcium, oxalate, uric acid) exceed their solubility product in the urine ^[23]^D5.
Nucleation: Solute molecules aggregate into microscopic crystals. This is often promoted by urinary proteins such as CD44 antigen, galectin-3-binding protein, and protein AMBP ^[37]^C4.
Crystal Growth and Aggregation: Small nuclei grow and clump together, a process facilitated by oxidative stress and cell-adhesion molecule binding ^[32]^C4.
Retention: Crystals must adhere to the renal epithelium or be trapped within the collecting system to avoid being flushed out by urine flow ^[17]^D5.

Randall's Plaque and Interstitial Mechanisms

In idiopathic calcium oxalate (CaOx) stone formers, the majority of stones originate as attached deposits on Randall's plaque ^[22]^C4. These plaques are interstitial calcium phosphate (hydroxyapatite) deposits that begin in the basement membrane of the thin loops of Henle and migrate to the subepithelial space of the renal papilla ^[22]^C4. When the overlying urothelium erodes, the plaque is exposed to supersaturated urine, serving as a tethered nidus for CaOx deposition ^[22]^C4. Micro-computed tomography (micro-CT) analysis of unattached stones frequently reveals internal regions of calcium phosphate, confirming they originated as attached papillary stones before detaching into the collecting system ^[22]^C4.

Cellular and Molecular Mediators

Stone formation is not merely a passive chemical precipitation but an active biological process involving mitochondrial dysfunction and inflammatory signaling ^[17]^D5^[38]^D5.

Oxidative Stress: CaOx crystals induce renal tubular damage by activating the PKCα/NADPH oxidase pathway, leading to the production of reactive oxygen species (ROS) ^[38]^D5.
Inflammation: Crystal-cell interactions trigger the NLRP3 inflammasome, which drives the release of pro-inflammatory cytokines ^[17]^D5. Intrarenal mRNA expression of monocyte chemoattractant protein-1 (MCP-1) and interleukin-6 (IL-6) is significantly elevated in stone-adjacent tissues ^[21]^C4.
Genetic Susceptibility: Polygenic factors influence calcium transport. Variants in the SLC34A1 gene (encoding the sodium-phosphate cotransporter NaPi-IIa) lead to and nephrocalcinosis ^[34]^C4. Other candidate genes include the calcium-sensing receptor, vitamin D receptor, and claudin-16 ^[16]^D5.

Obstructive Physiology and Pressure Dynamics

Once a stone enters the ureter, it causes mechanical obstruction, leading to proximal hydronephrosis and increased intrarenal pressure (IRP). During surgical interventions like ureteroscopy, the median IRP is approximately 28.5 mmHg, but it can reach maximums of 174 mmHg ^[19]^C4. Sustained high pressure and obstruction can lead to uroseptic shock and multiple organ dysfunction, particularly in high-risk states like pregnancy ^[35]^C4. In cases of calculous anuria, bilateral obstruction results in a rapid decline in GFR and acute kidney injury ^[24]^C4.

Metabolic and Secondary Drivers

Secondary stone formation often results from systemic metabolic derangements that alter urinary chemistry ^[28]^D5^[36]^D5.

Condition	Primary Mechanism	Urinary Finding
Malabsorptive States (IBD, Bariatric Surgery)	Increased intestinal oxalate absorption and decreased fluid absorption ^[28]^D5	, hypocitraturia
(including Normocalcemic)	PTH-mediated bone resorption and increased renal calcium filtration ^[30]^D5^[36]^D5	Hypercalciuria
Cystinuria	Defective renal tubular reabsorption of dibasic amino acids ^[24]^C4	Cystine supersaturation
Urinary Stasis (UPJO, Horseshoe Kidney)	Prolonged transit time allowing for crystal aggregation and infection ^[27]^D5	Variable; often infectious stones

Pearl: Nephrolithiasis is an inflammatory disease as much as a metabolic one; elevated intrarenal MCP-1 and IL-6 levels correlate directly with the degree of renal impairment and tubular damage ^[21]^C4.

Molecular and Genetic Drivers of Nephrolithiasis

Factor	Role in Pathogenesis	Clinical Association
SLC34A1	Sodium-phosphate cotransport defect	Infantile hypercalcemia, hypercalciuria ^[34]^C4
MCP-1 / IL-6	Pro-inflammatory cytokine signaling	Progression of renal impairment ^[21]^C4
miR-223-3p	Exosomal miRNA regulating oxidative stress	Elevated in CaOx stone patients ^[32]^C4
Nesfatin-1	Bioactive peptide (protective)	Downregulated in stone disease ^[38]^D5

Epidemiology, Etiology & Risk Factors

▸Global prevalence is rising, currently affecting up to 13% of North Americans, driven by metabolic syndrome, obesity, and diabetes.
▸Ambient temperature is a potent environmental driver, with higher temperatures increasing urinary calcium excretion and stone-related events (RR 1.31).
▸Neurological impairment and bladder management strategies, particularly indwelling catheters, significantly elevate the risk of calcium phosphate and struvite stones.

HY High Yield: In children, the incidence of nephrolithiasis has increased by 6% to 10% annually over the last 25 years, reaching 50 per 100,000 adolescents [47].

! Warning: Ceftriaxone-induced urolithiasis occurs in approximately 7% of pediatric patients, with some retrospective Asian cohorts reporting rates as high as 34% [64].

The global burden of nephrolithiasis is substantial and rising, with prevalence rates ranging from 7% to 13% in North America, 5% to 9% in Europe, and 1% to 5% in Asia ^[70]^D5. This increasing incidence is attributed to population growth and the rising prevalence of metabolic comorbidities ^[70]^D5. While historically more common in men, the gender gap is narrowing ^[70]^D5. In the southeastern United States, white men exhibit the highest risk (incidence 5.98 per 1000 person-years), whereas no significant sex difference in risk is observed among black populations ^[53]^B2b.

Metabolic and Systemic Risk Factors

Nephrolithiasis is increasingly recognized as a systemic disorder linked to metabolic health and cardiovascular risk. A history of stones is associated with an increased risk of stroke (HR 1.43, 95% CI 1.35-1.50) ^[57]^B2b and chronic kidney disease, particularly in women (OR 1.76) ^[49]^B2c.

Metabolic Syndrome: Positively associated with stone formation (OR 1.30), with (OR 1.29) and (OR 1.15) serving as independent drivers ^[52]^B3b.
Obesity and Diabetes: Both are established drivers of the rising global prevalence ^[70]^D5.
Vitamin D Deficiency: Serum 25-hydroxyvitamin D levels <20 ng/mL are associated with higher odds of idiopathic calcium nephrolithiasis (OR 2.29) ^[61]^B3b.
Oxidative Balance: A higher Oxidative Balance Score (OBS), reflecting a diet and lifestyle rich in antioxidants, is associated with a 23% lower risk of incident stones ^[67]^B2b.

Environmental and Seasonal Drivers

Ambient temperature significantly influences stone risk through physiological changes in urine composition. Increasing temperature is associated with elevated urinary calcium excretion and higher supersaturation of calcium oxalate and calcium phosphate ^[59]^B2b.

Seasonal Peaks: Presentations for renal colic peak during summer months in the Northern Hemisphere and from December to March in Australia ^[65]^A1a.
Temperature Effect: Meta-analysis shows a pooled relative risk of 1.31 for urolithiasis presentation at higher ambient temperatures ^[65]^A1a.
Dehydration: Low water intake is a primary modifiable driver; increasing fluid intake can reduce stone burden by approximately 40% ^[58]^B2b.

Genetic and Anatomical Etiologies

While most stone disease is polygenic, roughly 50% of the risk is heritable ^[45]^D5. Genetic susceptibility can modify the impact of lifestyle factors, with the protective effect of a high OBS being more pronounced in those with low genetic risk ^[67]^B2b.

Monogenic Causes: At least 27 genes are known to cause or influence nephrolithiasis, including rare conditions like ^[45]^D5^[66]^C4.
Neurological Disorders: Children with immobilization, UTIs, or neurological disorders have a stone incidence of 5% to 54% ^[43]^D5. In patients with , the use of indwelling catheters (OR 9.78) or intermittent catheterization (OR 3.50) are major risk factors ^[55]^B3b.
Surgical History: is associated with a significantly higher risk of postoperative stones compared to (OR 18.18) ^[56]^B3b.

Risk Factor Summary Table

Factor	Association (OR/RR/HR)	Evidence Level
Metabolic Syndrome	OR 1.30 ^[52]^B3b	3b
Vitamin D Deficiency (<20 ng/mL)	OR 2.29 ^[61]^B3b	3b
Radical	OR 18.18 ^[56]^B3b	3b
High Ambient Temperature	RR 1.31 ^[65]^A1a	1a
History of Urinary Stones (Stroke Risk)	HR 1.43 ^[57]^B2b	2b
Indwelling Catheter (in MS)	OR 9.78 ^[55]^B3b	3b

Pearl: Nephrolithiasis is a systemic marker of metabolic and cardiovascular health; a single stone event in a woman carries a 76% increased odds of developing chronic kidney disease ^[49]^B2c.

Pediatric Stone Composition

Stone Type	Frequency in Children
Calcium Oxalate	75-80%
Calcium Phosphate	5-10%
Struvite	10-20%
Uric Acid	5%
Cystine	Rare

Clinical Presentation

▸Renal colic is the primary symptom, but nonobstructing calyceal stones can also cause significant flank pain that improves after surgical removal.
▸Calculous anuria and infection in the setting of obstruction are critical red flags requiring immediate decompression.
▸Pediatric nephrolithiasis often presents with non-specific symptoms like emesis and has a high association with metabolic hypercalciuria (40%).

HY High Yield: In patients with a history of chronic opioid use, the threshold for seeking emergency care for stent-related symptoms is lower, with a significantly higher rate of unplanned ER visits (OR 3.64) [29].

! Warning: Bilateral obstructing stones can present as anuria and acute renal failure, particularly in pediatric patients, requiring prompt recognition and relief of obstruction [24].

Building upon the metabolic and environmental risk factors previously discussed, the clinical manifestation of nephrolithiasis ranges from incidental findings on imaging to surgical emergencies characterized by excruciating pain and systemic instability. While many stones remain asymptomatic for years, the transition to symptomatic disease often occurs abruptly when a calculus migrates into the ureter or obstructs a calyx.

Presenting Symptoms

The hallmark of symptomatic nephrolithiasis is renal colic, a sudden, severe pain typically localized to the flank. This pain often radiates anteriorly toward the groin or labia/scrotum as the stone descends the ureter.

Pain Characteristics: Flank pain is classically paroxysmal and associated with nausea and emesis ^[24]^C4. While traditionally attributed to obstruction, nonobstructing calyceal stones can also cause moderate to severe pain; their surgical removal has been shown to reduce mean pain scores from 5.5 to 1.8 and worst pain scores from 7.2 to 2.8 at 12 weeks postoperatively ^[79]^B2b.
Hematuria: Both macroscopic and microscopic hematuria are common. In pediatric cohorts, macroscopic hematuria is observed in approximately 28% of symptomatic patients ^[88]^C4.
Lower Urinary Tract Symptoms (LUTS): As stones approach the ureterovesical junction, patients may report dysuria, frequency, and urgency, mimicking a urinary tract infection ^[88]^C4.
Atypical Symptoms: Pediatric patients may present with abdominal distension or isolated emesis ^[24]^C4. In rare cases, extraintestinal manifestations of can present as penile or scrotal edema alongside nephrolithiasis ^[85]^C4.

Physical Examination and Red Flags

Physical examination often reveals costovertebral angle tenderness. However, the presence of certain systemic signs necessitates urgent intervention to prevent permanent renal damage or sepsis.

Calculous Anuria: Bilateral obstructing stones or a stone obstructing a solitary kidney can lead to complete anuria and acute renal failure ^[24]^C4^[86]^C4.
Infection: The triad of flank pain, fever, and pyuria suggests an infected obstructed system, a urological emergency.
Renal Dysfunction: Chronic or large staghorn calculi are associated with robust signs of inflammation and fibrosis, which correlate inversely with renal function ^[84]^B3b.

Phenotypic Variants and Special Populations

Variant	Key Features	Clinical Context
Asymptomatic Stones	Incidental finding; risk of symptomatic episodes ranges from 0% to 59.4% ^[77]^A1a.	Often found during imaging for unrelated issues.
Staghorn Calculi	Large, branched stones filling the renal pelvis; associated with chronic inflammation and epithelial-mesenchymal transition ^[84]^B3b.	High risk for renal function decline and xanthogranulomatous pyelonephritis ^[87]^C4.
Pediatric Stones	Higher prevalence of metabolic abnormalities; 40% may have ^[88]^C4.	Increasing incidence; often presents with emesis or anuria ^[24]^C4.
Crystalluria	Presence of crystals in urine; found in 4% of congenital heart disease patients and 7% of controls ^[89]^B3b.	Generally asymptomatic; does not predict medium-term cardiovascular events ^[89]^B3b.

Post-Procedural Symptoms

Patients undergoing definitive often experience a secondary phase of symptoms related to ureteral stents. These symptoms include dysuria, flank pain during voiding, and urgency. Silicone hydrocoated stents have been shown to reduce body pain scores by 25% compared to standard stents ^[74]^A1b. Chronic opioid use is a significant predictor of unplanned emergency room visits for these symptoms (OR 3.64) ^[29]^B3b.

Pearl: Stone size is a poor predictor of symptoms, but it strongly predicts the need for intervention; stones > 5 mm are significantly more likely to require surgical management than smaller calculi ^[77]^A1a.

Phenotypic Variants of Nephrolithiasis

Variant	Key Features	Clinical Context
Asymptomatic Stones	Incidental finding; risk of symptomatic episodes ranges from 0% to 59.4% ^[77]^A1a.	Often found during imaging for unrelated issues.
Staghorn Calculi	Large, branched stones; associated with chronic inflammation and fibrosis ^[84]^B3b.	High risk for renal function decline and xanthogranulomatous pyelonephritis ^[87]^C4.
Pediatric Stones	Higher prevalence of metabolic abnormalities; 40% may have hypercalciuria ^[88]^C4.	Increasing incidence; often presents with emesis or anuria ^[24]^C4.
Crystalluria	Presence of crystals in urine; found in 4% of CHD patients and 7% of controls ^[89]^B3b.	Generally asymptomatic; does not predict cardiovascular events ^[89]^B3b.

Diagnosis & Workup

▸Non-contrast CT is the gold standard for diagnosis, providing essential data on stone size, location, and density (Hounsfield Units) to guide surgical planning.
▸Ultrasound is the first-line modality for pediatric and pregnant populations but has a sensitivity of only 54% and often overestimates stone size compared to CT.
▸Urgent diagnostic findings requiring immediate intervention include obstructing stones associated with fever, solitary kidneys, or intractable pain.

Dx Diagnostic Essentials: Non-contrast computed tomography (NCCT) of the abdomen and pelvis is the gold-standard diagnostic test for nephrolithiasis.

HY High Yield: In pediatric patients, ceftriaxone use is a known risk factor for urolithiasis, with a pooled frequency of approximately 7% [64].

Establishing the diagnosis of nephrolithiasis requires a high-performance diagnostic engine that balances the sensitivity of cross-sectional imaging with the metabolic insights of laboratory analysis. While clinical presentation often guides the initial suspicion, the diagnostic pathway is primarily imaging-driven to confirm stone presence, size, and location, which dictates the subsequent surgical algorithm ^[10]^A1c^[11]^A1c.

History and Physical

Clinical evaluation focuses on identifying the classic paroxysms of renal colic and assessing for systemic complications.

Symptoms: Acute onset of severe, unilateral flank pain radiating to the groin, often associated with nausea and vomiting ^[42]^A1b.
Physical Signs: Costovertebral angle (CVA) tenderness is the hallmark finding.
Red Flags: Fever, hypotension, or tachycardia in the setting of suspected obstruction suggest urosepsis or emphysematous pyelonephritis, particularly in diabetic patients ^[113]^C4.
Timeline: Symptoms typically evolve over hours; persistent pain despite or anuria in a patient with a solitary kidney upgrades the urgency of the workup ^[10]^A1c^[11]^A1c.

Imaging Modalities

Imaging is the cornerstone of diagnosis, used to determine stone burden and the degree of hydronephrosis.

Non-contrast Computed Tomography (NCCT): The gold-standard for diagnosis due to its high sensitivity and specificity. It provides critical data on stone density (Hounsfield Units), which predicts shock wave lithotripsy (SWL) success ^[115]^D5.
Ultrasonography (US): Recommended as the initial imaging study in children and pregnant patients to minimize radiation ^[47]^D5^[104]^D5. While US reduces cumulative radiation exposure without increasing 30-day high-risk complications (0.4%), it has a lower sensitivity (54%) compared to CT and frequently overestimates stone size in the 0-10 mm range ^[42]^A1b^[106]^B3b.
KUB (Kidney, Ureter, Bladder) Radiography: Often used in conjunction with US to increase sensitivity to 78% and to determine if a stone is radiopaque for future fluoroscopic monitoring ^[106]^B3b.

Laboratory Studies

Laboratory workup identifies the metabolic drivers of stone formation and assesses renal function.

Test	Finding / Significance
Urinalysis	Hematuria (common but not universal), pH (low pH suggests uric acid; high pH >7.2 suggests struvite), and microscopy for crystals ^[105]^B3b.
Serum Creatinine	Assesses baseline renal function and identifies acute kidney injury from obstruction ^[107]^B3b.
	Leukocytosis may indicate concomitant infection or urosepsis ^[113]^C4.
24-Hour Urine Collection	Essential for recurrent or high-risk formers; measures calcium, oxalate, citrate, sodium, and uric acid ^[105]^B3b.
Stone Analysis	Chemical analysis of passed or retrieved stones is the most direct way to determine etiology (e.g., calcium oxalate, cystine, or uric acid) ^[66]^C4.

Diagnostic Algorithm

Initial Assessment: Perform history and physical; obtain urinalysis and serum creatinine ^[10]^A1c.
Primary Imaging: Order low-dose NCCT for most adults. Use ultrasound as the first-line for children and pregnant patients ^[47]^D5^[104]^D5.
Risk Stratification: Identify "urgent" stones (obstructing stone with infection, solitary kidney, or intractable pain) requiring immediate decompression ^[11]^A1c.
Metabolic Workup: For first-time formers, basic labs suffice. For recurrent, bilateral, or pediatric formers, perform a 24-hour urine metabolic profile and consider genetic testing for monogenic causes (e.g., NHERF1 mutations) ^[45]^D5^[109]^B3b.

Controversies and Guideline Disagreement

Question	Position A (AUA/EAU)	Position B (Emergency Medicine)	Strength	Implication
Initial Imaging	NCCT is preferred for definitive sizing and planning ^[10]^A1c^[11]^A1c.	US is sufficient for initial ED triage to reduce radiation ^[42]^A1b.	Moderate	US may lead to inappropriate counseling in 22% of cases due to sizing errors ^[106]^B3b.

Pearl: Ultrasound is the preferred initial test for children and pregnancy, but it misses nearly half of stones (46% false negative rate) and frequently overestimates the size of those it does find ^[106]^B3b.

Imaging Performance Comparison

Modality	Sensitivity	Specificity	Clinical Utility
NCCT	>95%	>95%	Gold standard; surgical planning; Hounsfield Units
Ultrasound	54% ^[106]^B3b	91% ^[106]^B3b	Initial test in children/pregnancy; misses small stones
KUB + US	78% ^[106]^B3b	N/A	Improved sensitivity over US alone; monitors radiopaque stones

Severity, Staging & Risk Stratification

▸Symptom duration >3 days and high stone density are independent predictors of the need for surgical intervention in acute ureteric colic.
▸Family history is a strong independent predictor of hypercalciuria (OR 2.15) and calcium oxalate monohydrate stone composition.
▸In moderate-to-high infectious risk patients undergoing PCNL, 7 days of preoperative antibiotics reduces sepsis risk compared to a 2-day course (OR 3.1).

HY High Yield: In children, a calcium-to-citrate ratio >0.64 is a significant marker for recurrent stone formation compared to solitary formers (0.41) or healthy controls (0.33).

Risk stratification in nephrolithiasis converts diagnostic findings into a graded tier that determines the necessity of surgical intervention versus the safety of surveillance. While acute obstructive uropathy is a medical emergency often accompanied by sepsis or acute renal failure ^[121]^D5, stable patients are stratified based on stone burden, location, and metabolic risk profiles to guide long-term .

Clinical and Stone-Related Predictors of Intervention

For patients presenting with acute ureteric colic, specific factors independently predict the failure of non-surgical surveillance and the eventual need for surgical intervention. A validated nomogram (AUC 0.802 to 0.833) identifies high-risk patients based on symptom duration, stone characteristics, and prior history ^[126]^B3b.

Symptom Duration: Symptoms lasting more than 3 days at presentation ^[126]^B3b.
Stone Burden: Increased stone size and density (Hounsfield Units) ^[126]^B3b.
Location: Specific ureteral positions (e.g., proximal vs. distal) ^[126]^B3b.
Medical Management: Failure to receive (e.g., ) ^[126]^B3b.
History: A positive history of previous renal calculi ^[126]^B3b.
Analgesic Requirements: While not reaching statistical significance, the need for opioid often correlates with surgical necessity ^[126]^B3b.

Metabolic and Genetic Risk Stratification

Risk stratification for recurrence relies on metabolic workup and family history. Family history is an independent predictor of specific metabolic abnormalities and stone types, suggesting a genetic predisposition that warrants targeted evaluation ^[127]^B3b.

: Higher prevalence in those with family history (27.9% vs. 12.5%, p = 0.034) ^[127]^B3b.
Pediatric Stratification: In children, the calcium-to-citrate ratio distinguishes solitary from recurrent stone formers. A mean ratio of 0.64 is seen in recurrent formers compared to 0.41 in solitary formers (p = 0.02) ^[120]^B3b.

Anatomical and Surgical Risk Tiers

Staging for surgical planning, particularly for lower pole stones (LPS), requires assessment of the infundibulopelvic angle (IPA), infundibulopelvic width (IPW), and infundibular length ^[99]^A1a. These factors influence the stone-free rate (SFR) and the choice between (SWL), (URS), and (PCNL).

Risk Factor	Clinical Impact	Evidence/Outcome
Staghorn Calculus	High infectious risk; associated with renal fibrosis and EMT ^[84]^B3b	Increased sepsis risk in PCNL (OR 3.1 if only 2 days of used) ^[117]^A1b
Stone Size >10 mm	Reduced efficacy of SWL for lower pole stones ^[40]^A1a	PCNL and RIRS significantly more effective than SWL (RR 2.04 for PCNL) ^[40]^A1a
Stone Density <450 HU	Predictor of "pure" uric acid stones ^[125]^B3b	Probability >95% for pure UAS if nomogram score is 156; candidates for chemolysis ^[125]^B3b
Sarcoidosis	Clinically silent genitourinary involvement ^[119]^D5	May cause nephrolithiasis or obstructive uropathy; can confound malignancy staging ^[119]^D5

Infectious Risk Stratification

Patients undergoing PCNL must be stratified by infectious risk to determine the duration of preoperative prophylaxis. In moderate to high-risk populations (positive culture or indwelling tube), 7 days of preoperative antibiotics significantly reduces sepsis compared to 2 days (OR 3.1, 95%, p = 0.031) ^[117]^A1b. This is particularly critical in patients with staghorn calculi, which are associated with chronic inflammation and renal dysfunction ^[84]^B3b.

Pearl: A stone density <450 HU and age-related factors can predict pure uric acid composition with >95% probability, allowing for the selection of non-invasive oral chemolysis over surgical intervention ^[125]^B3b.

Predictors of Pure Uric Acid Stones for Chemolysis Selection

Variable	Finding in Pure UAS (≥95%)	Finding in Mixed UAS (50-90%)
Mean Stone Density	450 Hounsfield Units (HU)	600 Hounsfield Units (HU)
Radiopacity	24% radiopaque	58% radiopaque
Stone Size	Typically larger	Typically smaller
Patient Age	Older	Younger

Acute Management & Decompression

▸Emergency decompression via ureteral stent or PCN is mandatory for obstructed systems with signs of infection or urosepsis.
▸NSAIDs are non-inferior to opioids for renal colic and postoperative pain, with lower risks of unplanned clinical encounters.
▸Silodosin 8 mg improves spontaneous passage rates specifically for distal ureteral stones 4-10 mm.

! Warning: Do NOT delay decompression in patients with fever and hydronephrosis; mortality in septic multi-organ failure remains 20% even with intervention [135].

Rx Drug of Choice: NSAIDs (e.g., [[ketorolac]]) are the first-line choice for renal colic pain, demonstrating superior value-based outcomes and reduced ED returns compared to opioids [132, 143].

Urgent decompression is mandatory when nephrolithiasis is complicated by an obstructed, infected collecting system, as delayed intervention in the setting of urosepsis carries a high mortality rate ^[135]^C4. While most patients with symptomatic stones can be managed non-operatively, the presence of systemic infection, solitary kidney obstruction, or bilateral obstruction necessitates immediate surgical drainage to prevent multi-organ failure and death ^[129]^A1c^[135]^C4.

Step 1: Initial Assessment and Triage

Clinicians must differentiate between uncomplicated renal colic and genitourinary emergencies. The CLAD-MB score (Complicated UroLithiasis and Alternative Diagnoses - Modified with Biology) identifies patients at high risk for surgery within 7 days ^[137]^B2b.

High-risk criteria for urgent surgery (CLAD-MB components):
Temperature > 37.8 °C (OR 4.2) ^[137]^B2b.
CRP ≥ 50 mg/mL (OR 2.8) ^[137]^B2b.
Leukocyte count ≥ 12 G/L (OR 1.72) ^[137]^B2b.
Elevated (OR 5.46) ^[137]^B2b.
Pain score > 7/10 ^[137]^B2b.

Step 2: Emergency Decompression

For the obstructed, infected system, the AUA and EAU guidelines mandate immediate drainage via either a retrograde or (PCN) ^[129]^A1c^[130]^A1c.

Modality Selection: In a retrospective analysis of emergency nephrectomies for urosepsis, 52% to 69% of patients had undergone prior endourological drainage (PCN or stent), yet mortality remained 20% in those with septic multi-organ failure ^[135]^C4.
Pregnancy Considerations: While ultrasound is the first-line imaging ^[141]^D5, if intervention is required, initial PCN placement is associated with significantly higher total radiation exposure (286.9 mGy) compared to stenting (3.7 mGy) or primary (0.2 mGy, P <.001) ^[147]^B3b. PCN in pregnancy also carries a 40% dysfunction rate ^[147]^B3b.

Step 3: Acute Pain

Non-opioid is the preferred first-line therapy for acute renal colic and postoperative pain ^[132]^A1b^[143]^B2b.

NSAIDs: The STONE Pathway evaluation demonstrated that guideline-concordant use of (90% vs 62%) reduced 30-day ED returns from 13% to 2% (P =.01) ^[143]^B2b.
Non-inferiority: is non-inferior to -acetaminophen for postoperative pain (mean pain score 3.20 vs 4.17, P = 0.018) ^[132]^A1b.

Step 4: Medical Expulsive Therapy (MET)

For distal ureteral stones 4-10 mm, selective alpha-blockers may facilitate passage ^[39]^A1b.

8 mg: While it does not improve passage rates for the entire ureter (52% vs 44%, P = 0.2), it significantly increases the rate of distal ureteral stone passage (P = 0.01) ^[39]^A1b.

Step 5: Transition to Definitive Management

Once the acute infection or obstruction is stabilized, definitive stone clearance is planned. Pre-stenting before retrograde intrarenal surgery (RIRS) significantly reduces operative time (58.8 min vs 68.6 min, P =.001) and increases the stone-free rate (85.3% vs 64.7%) ^[140]^A1b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Initial Imaging in ED	AUA/NEJM ^[42]^A1b: Ultrasonography is a safe initial alternative to CT, reducing radiation without missing high-risk diagnoses.	Standard Practice ^[131]^A1b: 78% of patients still undergo CT before surgical intervention even if US was performed first.	Moderate	US is preferred for triage, but CT remains the gold standard for surgical planning.
Pre-stenting for RIRS	Ansari et al. ^[140]^A1b: Routine pre-stenting improves stone-free rates and reduces operative time.	General Practice ^[140]^A1b: Often avoided to prevent a two-stage procedure and stent-related morbidity.	Moderate	Pre-stenting is beneficial for complex stones but adds a procedural step.

Pearl: In the setting of an obstructed, infected kidney, emergency decompression (stent or PCN) is a life-saving priority that must precede definitive stone fragmentation ^[129]^A1c^[135]^C4.

Analgesic Dosing and Monitoring

Starting Dose	Key Monitoring	Evidence Level
15-30 mg IV/IM	Renal function, GI bleeding	1b ^[132]^A1b
8 mg PO daily	Orthostatic hypotension, retrograde ejaculation	1b ^[39]^A1b
5 mg PO	Respiratory depression, constipation	1b ^[132]^A1b

Long-term & Definitive Management: Medical vs Endourologic/Surgical

▸PCNL achieves superior stone-free rates compared to URS and SWL, particularly for stones >20 mm (RR 1.13 vs URS).
▸Active intervention for asymptomatic stones reduces the odds of subsequent surgery (OR 0.45) without increasing adverse events.
▸Intraoperative IV ketorolac reduces perioperative narcotic requirements by 37% during ureteroscopy.

Rx Drug of Choice: For medical expulsive therapy (MET) of distal ureteral stones, **silodosin 8 mg daily** significantly increases passage rates compared to placebo (p=0.01) [39].

! Warning: Hydrochlorothiazide use for stone prevention is associated with increased risks of hypokalemia, gout, and new-onset diabetes mellitus [41].

Definitive of nephrolithiasis transitions from acute decompression to a choice between metabolic prevention and surgical extirpation, guided by stone size, location, and patient anatomy ^[9]^A1c^[10]^A1c. While medical therapies aim to reduce recurrence, surgical interventions prioritize achieving a stone-free state (SFR) through varying degrees of invasiveness ^[110]^A1a^[111]^A1a.

Step 1: Surveillance and Medical Prevention

Observation is a viable strategy for asymptomatic renal stones, though active intervention may reduce the risk of subsequent surgery ^[14]^A1a. In a meta-analysis of 6 RCTs (N=592), active intervention for asymptomatic stones reduced the odds of subsequent surgery (OR 0.45, 95% CI 0.25-0.80) compared to observation ^[14]^A1a.

For recurrent calcium-containing stones, metabolic prevention traditionally includes diuretics, though recent evidence has challenged their efficacy. In the NOSTONE trial (N=416), hydrochlorothiazide 50 mg daily did not significantly reduce recurrence compared to placebo (rate ratio 0.92, 95% CI 0.63-1.36; P=0.66) ^[41]^A1b. Conversely, 1 mEq/kg per day may lower recurrence rates in children (RR 0.19, 95% CI 0.06-0.60), corresponding to 270 fewer recurrences per 1000 children ^[62]^A1a.

Step 2: Selection of Surgical Modality

The AUA and EAU guidelines recommend selecting surgical modalities based on stone burden and location ^[9]^A1c^[129]^A1c^[159]^A1c.

Shock Wave Lithotripsy (SWL): Preferred for small, non-lower pole stones. In children <6 years with stones 10-20 mm, SWL achieved a significantly lower SFR (33.33%) compared to mini-PCNL (93.33%, P<0.001) ^[60]^A1b.
Percutaneous Nephrolithotomy (PCNL): The gold standard for stones >20 mm or complex calculi. PCNL achieves the highest SFR compared to URS and SWL (RR 1.13 for PCNL vs URS, P<0.0001) ^[111]^A1a.

Step 3: Optimization of Endourologic Outcomes

Technique modifications significantly impact success rates and morbidity. For lower pole stones <2 cm, displacing the stone to the upper pole during URS increases SFR (RR 1.21) ^[99]^A1a. The use of a (UAS) can lower intrarenal pressure (IRP), as smaller 10/12-F sheaths do not reduce pressure as effectively as 11/13-F or 12/14-F models (P<0.001) ^[19]^C4 (4).

Step 4: Perioperative Pain and Safety

Multimodal is critical for reducing opioid requirements. Intraoperative IV ketorolac during URS is associated with a 37% reduction in narcotic requirements (P<0.02) ^[78]^A1b. For PCNL, preoperative paravertebral block (PVB) significantly reduces both intraoperative and postoperative opioid use ^[150]^A1b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
First-line for 10-20 mm lower pole stones	AUA 2026, URS or SWL are both acceptable first-line options ^[9]^A1c	EAU/Cochrane, PCNL or RIRS are superior to SWL for stones >10 mm (RR 2.04 for PCNL vs SWL) ^[40]^A1a^[110]^A1a	Moderate	SWL remains popular for its non-invasiveness despite lower SFR in this subgroup.
Thiazides for prevention	AUA/EAU, Recommend thiazides to reduce calcium stone recurrence ^[159]^A1c	NOSTONE Trial, Found no significant benefit for hydrochlorothiazide at doses up to 50 mg ^[41]^A1b	Strong	Clinicians may need to re-evaluate the role of HCTZ vs other thiazide-like diuretics.

Pearl: PCNL provides the highest stone-free rates for large or lower-pole calculi but carries higher morbidity; for stones <10 mm, URS and SWL offer lower-risk profiles with acceptable efficacy ^[40]^A1a^[110]^A1a^[111]^A1a.

Surgical Modality Comparison for Renal Stones

Modality	Primary Indication	Stone-Free Rate (SFR)	Complication Rate	Evidence Level
SWL	Renal stones <20 mm (non-lower pole)	Lowest (approx. 33-40% for LP)	Lowest	1a ^[40]^A1a^[110]^A1a
URS / RIRS	Ureteral or renal stones ≤20 mm	Intermediate (77-80%)	Low	1a ^[151]^A1b^[162]^A1a
PCNL	Stones >20 mm, staghorn calculi	Highest (85-95%)	Highest	1a ^[110]^A1a^[111]^A1a
Mini-PCNL	Stones 10-30 mm	High (89-95%)	Moderate	1a ^[153]^A1a^[101]^A1a

Dosing for Metabolic Stone Prevention

Starting dose	Target / max dose	Renal adjustment	Key monitoring
12.5 mg PO daily	50 mg PO daily	Avoid if Cr >150% baseline	K+, Glucose, Uric acid ^[41]^A1b
1 mEq/kg daily (pediatric)	Varies by urine citrate	Monitor eGFR	Urinary pH, Citrate ^[62]^A1a
8 mg PO daily	8 mg PO daily	eGFR 30-50: 4 mg; <30: Avoid	Retrograde ejaculation ^[39]^A1b

History and Evolution of Treatment

▸Mini-PCNL provides a significantly higher stone-free rate (93.33%) than SWL (33.33%) in pediatric patients with 1-2 cm stones.
▸The NOSTONE trial found no significant dose-response effect for hydrochlorothiazide (12.5-50 mg) in preventing calcium stone recurrence compared to placebo.
▸Medical dissolution therapy for uric acid stones using potassium citrate achieves complete resolution in approximately 67% of patients.

HY High Yield: In patients with primary hyperparathyroidism, parathyroidectomy significantly reduces long-term stone recurrence, though the risk may be transiently elevated immediately post-surgery [92].

The of nephrolithiasis has transitioned from invasive open surgery to a paradigm of minimally invasive endourology and metabolically targeted prevention. While historical figures like President Lyndon B. Johnson required open surgical removal of stones three times during his career, modern practice is defined by the evidentiary shift toward shock wave lithotripsy (SWL), ureteroscopy (URS), and percutaneous nephrolithotomy (PCNL) ^[178]^D5.

The Rise of Minimally Invasive Surgery

The surgical landscape was revolutionized by the introduction of extracorporeal shock wave lithotripsy (SWL) and the refinement of endourologic techniques. In France, longitudinal data from 1977 to 1993 demonstrated that SWL was increasingly utilized for stones that might have previously been left to spontaneous discharge ^[171]^B2c.

PCNL vs. SWL: In pediatric populations (ages 6 months to 6 years), mini-PCNL has demonstrated a significantly higher stone-free rate (SFR) of 93.33% compared to 33.33% for SWL (p < 0.001) ^[60]^A1b.
RIRS vs. PCNL: Recent trials comparing flexible mini-PCNL (F-mPCNL) to retrograde intrarenal surgery (RIRS) for stones 1.5-3 cm found F-mPCNL achieved a superior SFR of 95.1% vs 77.8% (p < 0.001), though it was associated with longer hospital stays and higher postoperative pain ^[151]^A1b.
Laser Evolution: The transition from 200 μm to 365 μm holmium laser fibers has significantly shortened operative times, particularly for stones > 2 cm or those located in the lower pole ^[168]^A1b.

Evolution of Medical Expulsive Therapy (MET)

Selective α-blockers emerged as a cost-effective strategy to facilitate stone passage. While early enthusiasm was high, multi-institutional trials like the silodosin study (8 mg daily) showed no significant difference in overall passage rates (52% vs 44%, p=0.2) but did confirm a benefit specifically for distal ureteral stones (p=0.01) ^[39]^A1b. In pediatric patients, remains a recommended agent to increase spontaneous passage ^[47]^D5.

Landmark Trials in Metabolic Prevention

Preventive strategies have evolved from general dietary advice to specific pharmacologic interventions based on stone composition.

Thiazides: Long considered the cornerstone of calcium stone prevention, the NOSTONE trial recently challenged the dose-response relationship of . The study found no significant difference in recurrence between 12.5 mg, 25 mg, or 50 mg doses and placebo (p=0.66), with recurrence rates ranging from 49% to 59% across all groups ^[41]^A1b.
Urease Inhibitors: For struvite stones, the bacterial urease inhibitor (15 mg/kg/day) was proven to prevent stone doubling (0% vs 37% in placebo, p < 0.01), though high rates of adverse effects like tremulousness and phlebothrombosis limit its long-term use ^[167]^A1b.
Dietary Shifts: Meta-analyses have solidified the role of high fluid intake (urine output > 2.5 L/d) in reducing recurrence (RR 0.39, 95% CI 0.19-0.80) ^[165]^A1a. Modern perspectives suggest that the shift from Paleolithic diets (high potassium, low sodium) to modern diets (high sodium, high acid precursors) has forced the kidney to maintain homeostasis at the expense of increased stone risk ^[188]^D5.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Thiazide Efficacy	Standard of care for ^[164]^A1c.	NOSTONE trial showed no dose-response benefit ^[41]^A1b.	Moderate	Re-evaluating optimal dosing and patient selection.
Vitamin D Use	Repletion is safe and does not increase urinary calcium ^[176]^B2b.	Hypovitaminosis D is associated with a 2.29 OR for stones ^[61]^B3b.	Conditional	Balancing bone health with stone risk.
Imaging Choice	CT is the gold standard for accuracy ^[42]^A1b.	Ultrasound reduces radiation without missing high-risk diagnoses ^[42]^A1b.	Strong	US preferred as initial imaging in children ^[47]^D5.

Pearl: The therapeutic trend is moving toward "ultra-slim" instrumentation, such as 6.3 Fr digital ureteroscopes, which offer comparable stone-free rates to 7.5 Fr models while potentially reducing ureteral trauma ^[102]^A1b.

Evolution of Surgical Outcomes

Procedure	Stone Size	Stone-Free Rate (SFR)	Key Evidence
F-mPCNL	1.5-3 cm	95.1%	Superior to RIRS in single session ^[151]^A1b
RIRS	1.5-3 cm	77.8%	Lower pain, shorter stay than PCNL ^[151]^A1b
Mini-PCNL	1-2 cm (Pediatric)	93.33%	Superior to SWL in children < 6 years ^[60]^A1b
SWL	1-2 cm (Pediatric)	33.33%	Higher retreatment and auxiliary rates ^[60]^A1b

Endoscopic & Procedural Technique Considerations

▸Mini-PCNL provides a significantly higher stone-free rate (95.1%) than RIRS (77.8%) for renal stones between 1.5 and 3 cm.
▸Intraoperative IV ketorolac reduces total peri-operative narcotic requirements by 37% during ureteroscopy.
▸Ureteral access sheaths (UAS) larger than 10/12F are more effective at maintaining lower intrarenal pressures during flexible ureteroscopy.

HY High Yield: In pediatric patients (6 months to 6 years) with stones 10-20 mm, mini-PCNL achieves a significantly higher stone-free rate (93.33%) compared to SWL (33.33%) [60].

! Warning: Nephrostomy tube placement (standard PCNL) should be maintained if there are more than 2 access tracts, significant intraoperative bleeding, or collecting system perforation [155].

Modern surgical of nephrolithiasis has evolved from open procedures to a refined armamentarium of minimally invasive techniques, including (URS), (PCNL), and extracorporeal shock wave lithotripsy (SWL) ^[9]^A1c, ^[110]^A1a. Selection of the optimal modality is determined by stone characteristics, urinary tract anatomy, and patient-specific factors through shared decision-making ^[10]^A1c, ^[11]^A1c. While SWL remains the only truly non-invasive option, its single-treatment success rates are often lower than those of URS or PCNL ^[110]^A1a, ^[115]^D5.

Ureteroscopy and Retrograde Intrarenal Surgery (RIRS)

Ureteroscopy is the most common surgical intervention for nephrolithiasis, with approximately 83% of stone surgeries utilizing this modality ^[107]^B3b. Technical success is enhanced by standardized procedural steps and the use of advanced instrumentation ^[194]^C4.

Ureteral Access Sheaths (UAS): The use of a UAS (e.g., 10/12F to 14/16F) can increase irrigation flow and decrease intrapelvic pressure (IRP) during flexible ureteroscopy ^[98]^D5, ^[194]^C4. Smaller 10/12F sheaths may not lower IRP as effectively as 11/13F or 12/14F models ^[19]^C4.
Intrarenal Pressure (IRP) Monitoring: Median IRP during URS is approximately 28.5 mmHg, though maximum pressures can reach 174 mmHg ^[19]^C4. IRP typically remains below 60 mmHg for 92% of the procedure ^[19]^C4. Higher pressures are associated with tight ureters and lack of pre-stenting ^[19]^C4.
Lower Pole Stone Management: For stones <2 cm in the lower pole, displacing the stone to the upper pole prior to lithotripsy significantly improves stone-free rates (SFR) compared to in situ treatment (RR 1.21, p < 0.001), despite a mean increase in operative time of 5.62 minutes ^[99]^A1a.
Scope Diameter: Ultra-slim 6.3 Fr digital ureteroscopes demonstrate comparable feasibility, safety, and manoeuvrability to standard 7.5 Fr models for stones <1.5 cm ^[102]^A1b.

Percutaneous Nephrolithotomy (PCNL) and Miniaturization

PCNL is the preferred modality for larger stone burdens, typically those >1.5 cm to 2 cm ^[158]^D5. Miniaturized versions (mini-PCNL, micro-PCNL) aim to reduce morbidity while maintaining high efficacy ^[153]^A1a, ^[160]^C4.

Mini-PCNL vs. RIRS: For stones 1.5-3 cm, mini-PCNL achieves a superior SFR (95.1%) compared to RIRS (77.8%, p < 0.001) in a single session ^[151]^A1b. Mini-PCNL is also associated with shorter operative times (47.6 vs. 59.3 minutes) but longer hospital stays ^[151]^A1b, ^[153]^A1a.
Micro-PCNL: This technique is effective for solitary stones with volumes <1000 mm³ ^[160]^C4. Stone number, volume, and density are significant predictors of clearance ^[160]^C4.
Tubeless PCNL: Omitting a nephrostomy tube at the conclusion of the procedure is safe in uneventful cases and is associated with less pain, lower costs, and shorter hospital stays ^[155]^D5. Standard nephrostomy remains indicated if >2 access tracts are used or if significant bleeding occurs ^[155]^D5.

Intraoperative Optimization and Safety

Pain Management: Intraoperative IV (Toradol) at induction reduces peri-operative narcotic requirements by 37% (22.2 vs. 30.4 combined MME, p < 0.02) ^[78]^A1b.
Radiation Safety: PCNL often involves higher radiation exposure than URS ^[104]^D5. Exposure can be minimized using ultrasound guidance, low-dose CT protocols, and the "as low as reasonably achievable" (ALARA) principle ^[104]^D5.
Retropulsion Control: Increasing the patient's angle of inclination (e.g., 10° to 40°) can effectively reduce laser-induced stone retropulsion to <1 cm in vitro ^[108]^D5.

Comparative Outcomes by Modality

Outcome	SWL	URS	PCNL
Stone-Free Rate	Lowest ^[111]^A1a	Intermediate ^[111]^A1a	Highest ^[111]^A1a
Invasiveness	Non-invasive ^[115]^D5	Minimally invasive ^[110]^A1a	Most invasive ^[110]^A1a
Retreatment Rate	Highest ^[111]^A1a	Lowest ^[111]^A1a	Intermediate ^[111]^A1a
Cost	Lowest ^[111]^A1a	Intermediate ^[111]^A1a	Highest ^[111]^A1a

Special Anatomical Considerations

Congenital anomalies such as horseshoe kidneys, ectopic kidneys, and (UPJO) increase the risk of stone formation due to urinary stasis ^[27]^D5. These cases often require specialized approaches, such as combined robotic pyeloplasty and stone removal or PCNL when endoscopic access is limited by anatomy ^[27]^D5, ^[163]^C4.

Pearl: For lower pole stones <2 cm, actively displacing the fragment to the upper pole before lithotripsy significantly increases the likelihood of a stone-free outcome (RR 1.21) with only a marginal increase in operative time ^[99]^A1a.

Comparison of Primary Stone Treatment Modalities

Feature	SWL	URS	PCNL
Primary Indication	Stones <1.5-2 cm ^[158]^D5	Ureteral or renal stones ^[107]^B3b	Stones >1.5-2 cm ^[158]^D5
Success Rate (SFR)	Lower (RR 0.67 vs PCNL) ^[110]^A1a	High ^[111]^A1a	Highest ^[111]^A1a
Complication Rate	Lowest ^[110]^A1a	Low ^[111]^A1a	Highest ^[111]^A1a
Hospital Stay	Shortest/Outpatient ^[111]^A1a	Short ^[153]^A1a	Longest ^[153]^A1a

Complications

▸Single-session bilateral RIRS increases overall complication rates and unplanned interventions compared to staged procedures, despite similar stone-free rates.
▸Thiazide prophylaxis for calcium stones carries a dose-independent risk of hypokalemia, gout, and new-onset diabetes mellitus.
▸Cystinuria is associated with significantly higher procedural burden and reduced renal function compared to idiopathic calcium stone disease.

HY High Yield: In patients with recurrent calcium stones, hydrochlorothiazide at doses of 12.5 mg, 25 mg, or 50 mg daily did not show a significant dose-response effect in preventing recurrence compared to placebo in a landmark trial (P=0.66) [41].

! Warning: Preoperative positive urine culture is a significant risk factor for postoperative complications following pyeloplasty or stone-related reconstructions (19% vs 6% in sterile cultures) [4].

Complications of nephrolithiasis arise from both the natural history of the disease and the sequelae of surgical and medical interventions. While many stones remain asymptomatic, surveillance of untreated calculi carries a risk of disease progression; active intervention in selected asymptomatic patients reduces the odds of subsequent surgery (OR 0.45, 95% CI 0.25-0.80) and stone growth (OR 0.24) ^[14]^A1a.

Procedural and Surgical Complications

Modern endourologic techniques, including (URS) and (PCNL), have distinct safety profiles. In pediatric populations, retrograde intrarenal surgery (RIRS) for stones ≥1 cm is associated with a 10% rate of Clavien-Dindo grade I-II complications, though grade III+ events are rare ^[162]^A1a. In adults, ultra-slim 6.3 Fr ureteroscopes may reduce potential ureteral trauma compared to 7.5 Fr models without compromising stone-free rates (SFR) ^[102]^A1b.

Bilateral stone disease presents a specific challenge regarding single-session versus staged procedures:

Same-session bilateral (ssPCNL): Offers significantly shorter hospital stays (mean difference -2.92 days) and reduced operative time compared to staged PCNL, with comparable SFR and minor complication rates ^[112]^A1a.

Medical and Metabolic Complications

Pharmacologic prophylaxis, while effective for prevention, introduces specific metabolic risks. (12.5 mg to 50 mg daily) is associated with increased rates of , , new-onset , and elevations in plasma creatinine ^[41]^A1b. In patients with infection-related stones, may reduce stone growth but is associated with a higher rate of adverse events (moderate SOE) ^[136]^A1a.

Long-term Sequelae and Recurrence

Recurrence is a primary long-term complication, particularly in high-risk populations. In children, the probability of symptomatic stone recurrence is 50% at 3 years following the index event ^[48]^B2b. In adults, factors such as age <60 years, female gender, malabsorptive disease, and diabetes independently predict repeat stone surgery ^[107]^B3b. Cystinuric patients face significantly higher morbidity, requiring more procedures over time (0.88 per year vs 0.23 in routine stone formers) and experiencing lower age-corrected creatinine clearance ^[198]^B3b.

Complication Summary Table

Complication	Frequency/Risk	Prevention/Mitigation	Management
Surgical Recurrence	24.5% over 4 years ^[107]^B3b	Metabolic workup, 24-h urine ^[164]^A1c	Repeat URS/PCNL/SWL
Post-URS Infection	Variable; higher with (+) culture ^[4]^C4	Preoperative ^[4]^C4	Antibiotics, drainage
Thiazide-induced DM	Increased vs placebo ^[41]^A1b	Monitoring glucose/electrolytes	Dose adjustment/cessation
Ureteral Stricture	Rare; iatrogenic or stone-related	Gentle instrumentation ^[102]^A1b	Appendiceal interposition ^[193]^C4

Pearl: The risk of symptomatic recurrence in pediatric patients reaches 50% within 3 years, but completing a 24-hour urinalysis is associated with a 60% decreased risk of recurrence (HR 0.40, 95% CI 0.18-0.91) ^[48]^B2b.

Predictors of Repeat Stone Surgery

Factor	Hazard Ratio (95% CI)
Age < 60 years	1.30 to 1.71 ^[107]^B3b
Female Gender	1.30 to 1.71 ^[107]^B3b
Malabsorptive GI Disease	1.30 to 1.71 ^[107]^B3b
Diabetes Mellitus	1.30 to 1.71 ^[107]^B3b
Bilateral Nephrolithiasis	1.30 to 1.71 ^[107]^B3b

Prognosis & Natural History

▸Surgical recurrence occurs in approximately 25% of patients within 4 years, with metabolic comorbidities and prior stone history serving as primary predictors.
▸Residual fragments > 4 mm significantly increase the likelihood of future surgical intervention (OR 1.50) compared to fragments ≤ 4 mm.
▸Standard endourological procedures (SWL, URS, PCNL) do not appear to impair long-term renal growth or function in pediatric or adult populations.

HY High Yield: While thiazides are guideline-recommended for recurrence prevention, the NOSTONE trial demonstrated that hydrochlorothiazide (12.5-50 mg) did not significantly reduce recurrence rates compared to placebo over 2.9 years [41].

Post-treatment outcomes and the natural history of asymptomatic nephrolithiasis are primarily defined by stone size, metabolic activity, and the presence of residual fragments. While acute complications are managed surgically, the long-term trajectory is characterized by a high risk of recurrence and the potential for progressive renal dysfunction if obstruction or infection persists ^[18]^D5^[164]^A1c.

Recurrence and Surgical Re-intervention

Nephrolithiasis is a highly recurrent pathology, affecting up to 15% of the global population ^[111]^A1a. In patients undergoing surgical intervention, the risk of repeat surgery is approximately 24.5% over a median follow-up of 3.9 years ^[107]^B3b. Most repeat procedures (82%) are performed for symptomatic recurrence rather than planned stages ^[107]^B3b. Factors associated with an increased hazard ratio (HR) for surgical recurrence (ranging from 1.30 to 1.71) include:

Age < 60 years
Female gender
Diabetes mellitus and obesity
Personal history of nephrolithiasis
Bilateral or multiple renal stones
Malabsorptive disease
Recurrent urinary tract infections (UTIs) ^[107]^B3b^[203]^B3b.

Natural History of Asymptomatic and Residual Stones

The incidental detection of small asymptomatic stones has risen, yet their progression is variable. The risk of developing symptoms ranges from 0% to 59.4%, while the risk of emergency admission is 14% to 19% ^[77]^A1a.

Outcome	Stone Size ≤ 4 mm	Stone Size > 4 mm	Statistical Significance
Intervention Rate	19% to 22%	22% to 47%	OR 1.50 (p < 0.001) ^[166]^A1a
Disease Progression	25% to 47%	26% to 88%	Not significant (p = 0.91) ^[166]^A1a
Symptomatic Episodes	Variable	Variable	No difference by size ^[77]^A1a

Active intervention for asymptomatic stones may reduce the odds of subsequent surgery (OR 0.45, 95% CI 0.25-0.80) and stone growth (OR 0.24) compared to observation, without increasing adverse events (OR 1.16) ^[14]^A1a.

Long-term Functional Outcomes

Modern endourological interventions do not appear to impair renal growth in pediatric populations; no significant differences in observed vs. predicted renal growth rates were found following (SWL), (URS), or (PCNL) over a mean 6.2-year follow-up ^[128]^B3b. In adults, untreated complex stones or late presentations in low-resource settings may lead to chronic kidney disease or end-stage renal failure due to chronic obstruction or urosepsis ^[18]^D5. Conversely, kidneys with proximal ureteral pathology and stones can be safely used for therapeutic living donor , with 100% graft and recipient survival reported at 40 months ^[201]^C4.

Impact of Prophylaxis on Recurrence

Secondary prevention significantly alters the natural history. High fluid intake to achieve urine output > 2.5 L/d reduces recurrence (RR 0.39, 95% CI 0.19-0.80) ^[165]^A1a. Pharmacotherapy with diuretics (e.g., 50 mg/d, OR 0.18) or alkali therapy may prevent recurrence in calcium stone formers ^[136]^A1a^[195]^A1a. However, recent landmark data for showed no significant dose-response effect at 12.5 mg, 25 mg, or 50 mg compared to placebo for a composite of symptomatic or radiologic recurrence (p = 0.66) ^[41]^A1b.

Pearl: Post-treatment residual fragments > 4 mm carry a significantly higher risk of future intervention (up to 47%) compared to smaller fragments, though size alone does not reliably predict the onset of symptoms ^[77]^A1a^[166]^A1a.

Predictors of Repeat Stone Surgery

Factor	Hazard Ratio (HR)	Clinical Implication
Age < 60 years	1.30-1.71	Higher lifetime risk of recurrence
Personal History	1.30-1.71	Indicates high metabolic activity
Bilateral Stones	1.30-1.71	Increased stone burden and recurrence risk
Diabetes/Obesity	1.30-1.71	Metabolic syndrome association

Special Populations & Pregnancy

▸Pediatric stone recurrence is high (50% at 3 years), but 24-hour urine metabolic testing reduces this risk by 60% (HR 0.40).
▸Percutaneous nephrostomy in pregnancy carries a significantly higher radiation burden (286.9 mGy) and complication rate compared to ureteroscopy or stenting.
▸Octogenarians undergoing PCNL have a nearly 3-fold higher rate of major complications (28.8%) compared to younger adults, primarily due to bleeding.

HY High Yield: In pediatric patients, low urine volume (89%) and hypocitraturia (68%) are the dominant metabolic drivers, rather than hypercalciuria (11%) [209].

! Warning: Ceftriaxone use in children is associated with a 7% pooled frequency of induced urolithiasis [64].

The natural history of nephrolithiasis is significantly altered by physiologic states such as pregnancy, pediatric development, and advanced age, necessitating modifications to standard diagnostic and surgical algorithms. While the core principles of remain focused on stone clearance and renal preservation, the risks of ionizing radiation, anesthetic exposure, and comorbid frailty dictate a more tailored approach ^[10]^A1c, ^[11]^A1c.

Pregnancy

Symptomatic nephrolithiasis affects less than 1% of pregnancies but presents unique diagnostic challenges due to physiologic hydronephrosis and the need to minimize fetal radiation ^[141]^D5. Maternal kidney stones are independently associated with several complications, including obesity (OR 4.4, 95% CI 2.1-9.0) and hypertensive disorders (OR 2.8) ^[214]^B3b.

Diagnosis: remains the first-line imaging modality of choice ^[141]^D5.
Management: Most patients (up to 80%) can be managed conservatively with hydration and . If intervention is required for obstruction or sepsis, options include placement, (PCN), or primary (URS) ^[141]^D5.
Radiation Considerations: Initial PCN placement is associated with significantly higher total radiation exposure per stone episode (286.9 mGy) compared to stents (3.7 mGy) or URS (0.2 mGy, p < 0.001) ^[147]^B3b. PCN also requires more frequent procedures due to a 40% dysfunction rate ^[147]^B3b.
Outcomes: While associated with higher rates of preeclampsia and cesarean delivery, nephrolithiasis does not appear to increase the risk of preterm delivery or adverse perinatal outcomes like low birth weight ^[214]^B3b.

Pediatrics

Pediatric stone disease is increasing in incidence and often involves metabolic or structural predispositions ^[48]^B2b, ^[209]^C4. Unlike adults, children have a high recurrence rate, with a 50% probability of symptomatic recurrence within 3 years of the first stone ^[48]^B2b.

Metabolic Profile: Modern pediatric cohorts show a high prevalence of low urine volume (89%) and hypocitraturia (68%), while is less common (11%) than historically reported ^[209]^C4. Completion of a 24-hour urine analysis is associated with a 60% decreased risk of recurrence (HR 0.40, 95% CI 0.18-0.91) ^[48]^B2b.
Surgical Selection: For stones 10-20 mm, mini-percutaneous nephrolithotomy (mini-PCNL) achieves a significantly higher stone-free rate (93.33%) compared to shock wave lithotripsy (SWL, 33.33%, p < 0.001) ^[60]^A1b. RIRS is also feasible for stones ≥1 cm, with a pooled initial stone-free rate of 79% ^[162]^A1a.
Renal Growth: Long-term data indicate that SWL, URS, and PCNL do not impair renal growth in children ^[128]^B3b.
Drug-Induced Stones: Ceftriaxone -induced urolithiasis occurs in approximately 7% of pediatric patients ^[64]^A1a.

Geriatric Patients

Management in the elderly (≥80 years) must account for increased comorbidities and a unique metabolic profile characterized by hypocitraturia, low urine pH, and low urine volume ^[215]^C4.

Surgical Risks: PCNL is feasible in octogenarians but carries a higher rate of Clavien II-IV complications (28.8% vs 10.4% in younger adults) and a higher transfusion rate (10.2% vs 2.3%, p < 0.001) ^[217]^B3b. Bleeding-related issues are the most common complication in this cohort (10.1%) ^[217]^B3b.
Empiric Therapy: In elderly patients where 24-hour urine collection is not feasible, empiric therapy should target their specific profile via increased hydration and low-dose alkali therapy ^[215]^C4.

Anticoagulated Patients

Patients requiring bridging anticoagulation during RIRS demonstrate lower surgical success rates and a significantly higher need for auxiliary procedures (p = 0.009) compared to those who simply discontinue therapy ^[210]^B3b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Primary URS in Pregnancy	Definitive treatment is safe and reduces radiation ^[147]^B3b.	Temporizing drainage (stent/PCN) is preferred to minimize anesthesia ^[141]^D5.	Moderate	Shift toward URS to avoid PCN-related radiation and tube exchanges.
Thiazides in	Suggested to reduce hypercalciuria ^[212]^A1a.	Pooled data show no significant reduction in urinary calcium ^[212]^A1a.	Low	Efficacy remains unproven; requires individualized monitoring.

Pearl: In pregnant patients requiring intervention, primary ureteroscopy or stenting is preferred over percutaneous nephrostomy to reduce total radiation exposure by over 98% ^[147]^B3b.

Surgical Outcomes in Special Populations

Population	Preferred Intervention	Key Outcome Metric	Evidence
Pregnancy	URS or Stent	URS radiation: 0.2 mGy vs PCN: 286.9 mGy	^[147]^B3b
Pediatrics (<6yr)	Mini-PCNL	SFR: 93.3% vs SWL: 33.3% (p < 0.001)	^[60]^A1b
Elderly (≥80yr)	PCNL	Complication rate: 28.8%; Transfusion: 10.2%	^[217]^B3b
Anticoagulated	RIRS (No bridging)	Bridging increases auxiliary procedure rate	^[210]^B3b

Prevention, Screening & Surveillance

▸High fluid intake to achieve a urine output > 2.5 L/d is the most effective non-pharmacologic intervention to prevent recurrence (RR 0.39).
▸Thiazide diuretics like [[chlorthalidone]] and [[hydrochlorothiazide]] reduce recurrence risk by 48% to 82%, though routine use is debated due to poor dose-response data and adverse effects.
▸Automated volumetric NCCT assessment provides 0% interobserver variability, making it superior to linear measurements for monitoring stone growth during surveillance.

HY High Yield: In patients with mild asymptomatic primary hyperparathyroidism, parathyroidectomy reduces serum calcium and increases BMD but has not been proven superior to active surveillance for reducing nephrolithiasis risk [223].

Following the of acute episodes or surgical clearance, the clinical focus shifts to mitigating the high risk of recurrence, which can affect up to 50% of patients over five years ^[58]^B2b. Secondary prevention relies on identifying modifiable risk factors through metabolic evaluation, though the prevalence of 24-hour urine testing remains low at approximately 7.4% to 7.9% ^[219]^B2c.

Primary Prevention and Cost-Effectiveness

Primary prevention strategies are theoretically cost-effective in populations where the annual stone incidence exceeds 4.3% or if the prevention cost is less than $23 per person per year ^[218]^B2c. High water intake is the primary modality for prevention; in a virtual cohort, universal high water intake was estimated to save €273 million annually and prevent 9,265 stones ^[58]^B2b. However, vitamin D and calcium supplementation are considered ineffective for primary prevention ^[220]^A1a.

Secondary Prevention: Dietary and Lifestyle Interventions

Increased fluid intake is the most robust intervention for reducing recurrence (RR 0.39, 95% CI 0.19-0.80) ^[165]^A1a. For adolescents, a 1 L increase in daily water intake is associated with a 710 mL increase in 24-hour urine output ^[226]^C4.

Fluid Goals: Target urine output > 2.5 L/d ^[165]^A1a.
Soft Drinks: Reducing intake lowers renal colic risk in high baseline consumers (34% vs 41%, p=0.023) ^[165]^A1a.
Dietary Composition: A diet featuring normal to high calcium, low animal protein, and low sodium reduces recurrence (20% vs 38%, p=0.03) ^[165]^A1a, ^[136]^A1a.
Health Literacy: Comprehensive dietary counseling is an independent predictor of higher prevention-specific health literacy (p=0.032), particularly regarding oxalate-specific knowledge ^[224]^C4.

Pharmacologic Prophylaxis

Pharmacotherapy is indicated for patients with recurrent stones or specific metabolic abnormalities. 1 mEq/kg/day may lower recurrence rates in children (RR 0.19, 95% CI 0.06-0.60) ^[62]^A1a. In adults, reduces recurrence risk by 79% ^[220]^A1a.

Thiazide and thiazide-like diuretics are frequently utilized, though recent evidence regarding their routine use is mixed ^[195]^A1a.

Medication	Effect Size (Recurrence)	95% CI	Evidence Note
50 mg/d	OR 0.18	0.04-0.88	No clear dose-dependency vs 25 mg ^[195]^A1a
50 mg/d	OR 0.52	0.29-0.93	No difference vs 12.5 mg or 25 mg ^[195]^A1a
4 mg/d	OR 0.26	0.10-0.68	Higher adverse effects (OR 49.96) ^[195]^A1a
	Reduced recurrence	Low SOE	For calcium oxalate/phosphate stones ^[136]^A1a

Surveillance of Asymptomatic and Residual Stones

Surveillance is a standard approach for small, asymptomatic stones, though active intervention may reduce subsequent surgery (OR 0.45, 95% CI 0.25-0.80) ^[14]^A1a. Stone size is not a reliable predictor of symptoms, but the risk of intervention is significantly higher for stones > 5 mm and > 10 mm ^[77]^A1a.

Imaging Modality: Automated volumetric assessment via NCCT is preferred over manual linear measurement for longitudinal surveillance as it eliminates interobserver variability (0% vs 16.4-20.3%) and amplifies small changes in stone burden ^[225]^B3b.
High-Risk Populations: Patients with (SCI) have a 17% annual recurrence rate if they have a prior stone history, compared to 2% in those without ^[69]^B2b.
Renal Transplant: De novo nephrolithiasis occurs in 1.0% of transplants; surveillance is an option for small stones, but antegrade surgical approaches yield the highest stone-free rates (86-96%) ^[222]^A1a.

Pearl: The "fluid prescription" for adolescents to reach a target urine output increase (dUOP) can be estimated by the formula: Additional Fluid = dUOP / 0.71 ^[226]^C4.

Predictors of Surgical Intervention During Surveillance

Predictor	Clinical Significance
Symptom Duration	> 3 days increases surgical likelihood ^[126]^B3b
Medical Therapy	Absence of increases surgical risk ^[126]^B3b
History	Positive history of previous renal calculi ^[126]^B3b
Stone Factors	Location, burden, and density are independent predictors ^[126]^B3b

References

[1]
Gambaro G, Croppi E, Coe F et al.. “Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement.” Journal of nephrology (2016). PMID: 27456839 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature
[2]
Elhaie M, Koozari A, Albeshan SM et al.. “Applications of artificial intelligence algorithms in ultrasound-based kidney stone detection, classification, prediction, and management: a systematic review.” Abdominal radiology (New York) (2026). PMID: 41801379 ↗
L5SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup, Endoscopic & Procedural Technique Considerations
[3]
Arroyave JS, Restrepo M, Cohen D et al.. “Appraisal of Spanish-language online patient education resources for kidney stones.” World journal of urology (2025). PMID: 40259134 ↗
L4OTHERCited in: Definition, Classification & Nomenclature
[4]
Szydełko T, Kasprzak J, Apoznański W et al.. “Clavien classification of complications after 150 laparoscopic pyeloplasties.” Urology (2011). PMID: 21316094 ↗
L4OTHERCited in: Definition, Classification & Nomenclature, Complications
[5]
Li KD, Pearce RJ, Sui W et al.. “Renal Autotransplantation: Association Between Preoperative Disease Duration and Surgical Outcomes.” Urology (2024). PMID: 38942394 ↗
L3OTHERCited in: Definition, Classification & Nomenclature
[6]
Hein S, Schoenthaler M, Wilhelm K et al.. “Ultralow Radiation Exposure During Flexible Ureteroscopy in Patients With Nephrolithiasis-How Far Can We Go?” Urology (2017). PMID: 28648966 ↗
L4OTHERCited in: Definition, Classification & Nomenclature
[7]
Lu S, Cottone CM, Yoon R et al.. “Endockscope: A Disruptive Endoscopic Technology.” Journal of endourology (2019). PMID: 31195831 ↗
L4OTHERCited in: Definition, Classification & Nomenclature
[8]
Borofsky MS, Dauw CA, Cohen A et al.. “Integration and utilization of modern technologies in nephrolithiasis research.” Nature reviews. Urology (2016). PMID: 27549355 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature
[9]
Pearle MS, Matlaga BR, Antonelli JA et al.. “Surgical Management of Kidney and Ureteral Stones: AUA Guideline (2026). Part III: Treatment of Patients With Kidney and/or Ureteral Stones and Future Directions.” The Journal of urology (2025). PMID: 41263325 ↗
L1GUIDELINECited in: Pathophysiology & Mechanism, Diagnosis & Workup, Acute Management & Decompression, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Endoscopic & Procedural Technique Considerations, Special Populations & Pregnancy
[10]
Pearle MS, Matlaga BR, Antonelli JA et al.. “Surgical Management of Kidney and Ureteral Stones: AUA Guideline (2026) Part I: Evaluation and Treatment of Patients With Kidney and/or Ureteral Stones.” The Journal of urology (2025). PMID: 41263323 ↗
L1GUIDELINECited in: Pathophysiology & Mechanism, Diagnosis & Workup, Acute Management & Decompression, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Endoscopic & Procedural Technique Considerations, Special Populations & Pregnancy
[11]
Pearle MS, Matlaga BR, Antonelli JA et al.. “Surgical Management of Kidney and Ureteral Stones: AUA Guideline (2026). Part II: Evaluation and Treatment of Patients With Kidney and/or Ureteral Stones.” The Journal of urology (2025). PMID: 41263322 ↗
L1GUIDELINECited in: Pathophysiology & Mechanism, Diagnosis & Workup, Acute Management & Decompression, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Endoscopic & Procedural Technique Considerations, Special Populations & Pregnancy
[12]
Robinson MR, Norris RD, Sur RL et al.. “Urolithiasis: not just a 2-legged animal disease.” The Journal of urology (2007). PMID: 17997446 ↗
L5SR_OBSCited in: Pathophysiology & Mechanism
[13]
Pais VM, Smith RE, Stedina EA et al.. “Does Omission of Ureteral Stents Increase Risk of Unplanned Return Visit? A Systematic Review and Meta-Analysis.” The Journal of urology (2016). PMID: 27287523 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Clinical Presentation
[14]
Tuo X, Ma Y, Ma Y et al.. “Intervention versus observation for asymptomatic kidney stones: a systematic review and meta-analysis of randomized controlled trials.” World journal of urology (2026). PMID: 42289039 ↗
L1SR_MA_RCTCited in: Pathophysiology & Mechanism, Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, Complications, Prognosis & Natural History, Prevention, Screening & Surveillance
[15]
Barghouthy Y, Corrales M, Doizi S et al.. “Tea and coffee consumption and pathophysiology related to kidney stone formation: a systematic review.” World journal of urology (2020). PMID: 33052484 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism
[16]
Vezzoli G, Soldati L, Gambaro G. “Update on primary hypercalciuria from a genetic perspective.” The Journal of urology (2008). PMID: 18343451 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[17]
Su B, Ren Y, Yao W et al.. “Mitochondrial dysfunction and NLRP3 inflammasome: key players in kidney stone formation.” BJU international (2024). PMID: 38967108 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, History and Evolution of Treatment
[18]
Watson G, Payne SR, Kunitsky K et al.. “Stone disease in low- and middle-income countries: could augmented reality have a role in its management?” BJU international (2022). PMID: 35993671 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, Endoscopic & Procedural Technique Considerations, Prognosis & Natural History, Special Populations & Pregnancy
[19]
Bhojani N, Koo KC, Bensaadi K et al.. “Retrospective first-in-human use of the LithoVue™ Elite ureteroscope to measure intrarenal pressure.” BJU international (2023). PMID: 37667553 ↗
L4OTHERCited in: Pathophysiology & Mechanism, Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, Endoscopic & Procedural Technique Considerations
[20]
Baccala A, Lee U, Hegarty N et al.. “Laparoscopic partial nephrectomy for tumour in the presence of nephrolithiasis or pelvi-ureteric junction obstruction.” BJU international (2008). PMID: 18990171 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[21]
Boonla C, Hunapathed C, Bovornpadungkitti S et al.. “Messenger RNA expression of monocyte chemoattractant protein-1 and interleukin-6 in stone-containing kidneys.” BJU international (2008). PMID: 18241247 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[22]
Miller NL, Williams JC, Evan AP et al.. “In idiopathic calcium oxalate stone-formers, unattached stones show evidence of having originated as attached stones on Randall's plaque.” BJU international (2009). PMID: 19549258 ↗
L4OTHERCited in: Pathophysiology & Mechanism, Long-term & Definitive Management: Medical vs Endourologic/Surgical
[23]
Moe OW. “Kidney stones: pathophysiology and medical management.” Lancet (London, England) (2006). PMID: 16443041 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[24]
Chait AR, Hassig S, Cubillos J et al.. “Cystinuria Complicated by Anuria From Bilateral Obstructing Stones Requiring Bilateral Mini Percutaneous Nephrolithotomy in a 22-Month-Old.” Urology (2024). PMID: 38281667 ↗
L4CASE_REPORTCited in: Pathophysiology & Mechanism, Clinical Presentation, Special Populations & Pregnancy
[25]
Beland LE, Henry MA, Solomon T et al.. “Obstructing Nephrolithiasis in an 84-year-old Patient With a Diaphragmatic Herniated Ureter.” Urology (2018). PMID: 30472257 ↗
L4CASE_REPORTCited in: Pathophysiology & Mechanism
[26]
Scotland KB, Kroczak T, Pace KT et al.. “Stone technology: intracorporeal lithotripters.” World journal of urology (2017). PMID: 28608192 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term & Definitive Management: Medical vs Endourologic/Surgical, Endoscopic & Procedural Technique Considerations
[27]
Ergül RB, Ozervarli MF, Oba KC et al.. “Urinary tract anomalies and their role in pediatric stone formation.” World journal of urology (2025). PMID: 41083800 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Endoscopic & Procedural Technique Considerations, Special Populations & Pregnancy
[28]
İbis MA, Oktar A, Gokce MI. “Dietary advice for patients with bowel-related conditions and malabsorption.” World journal of urology (2023). PMID: 36648528 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[29]
Policastro C, Dispagna M, Smith G et al.. “Factors associated with unplanned clinical encounters for ureteral stent-related symptoms.” World journal of urology (2024). PMID: 38324162 ↗
L3OTHERCited in: Pathophysiology & Mechanism, Clinical Presentation, Acute Management & Decompression, History and Evolution of Treatment
[30]
Tasca A, Dalle Carbonare L, Nigro F et al.. “Bone disease in patients with primary hypercalciuria and calcium nephrolithiasis.” Urology (2009). PMID: 19428073 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[31]
Cohen AJ, Adamsky MA, Nottingham CU et al.. “Impact of Statin Intake on Kidney Stone Formation.” Urology (2018). PMID: 29421299 ↗
L3OTHERCited in: Pathophysiology & Mechanism
[32]
Yang Y, Wang Q, Xun Y et al.. “The Preliminary Exploration of What Role miRNAs Derived From Urinary Exosomes Play in Kidney Stone Formation.” Urology (2022). PMID: 35636636 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[33]
Cobb KD, Gomella PT, DiBianco JM et al.. “Are Emergently Placed Nephrostomy Tubes Suitable for Subsequent Percutaneous Endoscopic Renal Surgery?” Urology (2019). PMID: 30658069 ↗
L3OTHERCited in: Pathophysiology & Mechanism
[34]
Turan I, Atar M, Eltan M et al.. “Targeting Hypercalciuria in SLC34A1-Related Disorders: Impact of Oral Phosphate Therapy and Novel Genetic Insights in Pediatric Case Series.” Calcified tissue international (2026). PMID: 41543768 ↗
L4CASE_REPORTCited in: Pathophysiology & Mechanism
[35]
Chen H, Huang Z, Chen G et al.. “Case Report: Maternal near-miss-recovery from refractory septic shock with multiple organ dysfunction secondary to acute pyelonephritis in pregnancy.” Frontiers in medicine (2025). PMID: 41451099 ↗
L4CASE_REPORTCited in: Pathophysiology & Mechanism
[36]
Kalik SA, Abate EG, Cusano NE. “Normocalcemic Primary Hyperparathyroidism: An Evolving Understanding.” Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2026). PMID: 42419589 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[37]
Rattananinsruang P, Peerapen P, Phuangkham S et al.. “Unveiling potential natural promoters of calcium oxalate kidney stones in the urine via anion-exchange chromatography, crystal assays, and proteomics.” Molecular and cellular biochemistry (2026). PMID: 42418121 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[38]
Lahane GP, Bhat A, Kulkarni O et al.. “Nesfatin-1 mitigates calcium oxalate nephropathy in mice through GPR12 receptor modulation and PKCα/NADPH oxidase pathway inhibition.” Life sciences (2026). PMID: 42335987 ↗
L5OTHERCited in: Pathophysiology & Mechanism
[39]
Sur RL, Shore N, L'Esperance J et al.. “Silodosin to facilitate passage of ureteral stones: a multi-institutional, randomized, double-blinded, placebo-controlled trial.” European urology (2014). PMID: 25465978 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute Management & Decompression, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Prognosis & Natural History
[40]
Donaldson JF, Lardas M, Scrimgeour D et al.. “Systematic review and meta-analysis of the clinical effectiveness of shock wave lithotripsy, retrograde intrarenal surgery, and percutaneous nephrolithotomy for lower-pole renal stones.” European urology (2014). PMID: 25449204 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management: Medical vs Endourologic/Surgical, Prognosis & Natural History
[41]
Dhayat NA, Bonny O, Roth B et al.. “Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence.” The New England journal of medicine (2023). PMID: 36856614 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Complications, Prognosis & Natural History
[42]
Smith-Bindman R, Aubin C, Bailitz J et al.. “Ultrasonography versus computed tomography for suspected nephrolithiasis.” The New England journal of medicine (2014). PMID: 25229916 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute Management & Decompression, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment
[43]
Tozsin A, Akdere H, Guven S et al.. “A systematic review on urolithiasis in children with neurological disorders.” World journal of urology (2024). PMID: 39522107 ↗
L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management: Medical vs Endourologic/Surgical, Endoscopic & Procedural Technique Considerations, Special Populations & Pregnancy
[44]
Suarez Arbelaez MC, Monshine J, Porto JG et al.. “The emerging role of the urinary microbiome in benign noninfectious urological conditions: an up-to-date systematic review.” World journal of urology (2023). PMID: 37737900 ↗
L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications
[45]
Policastro LJ, Saggi SJ, Goldfarb DS et al.. “Personalized Intervention in Monogenic Stone Formers.” The Journal of urology (2017). PMID: 29061541 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, History and Evolution of Treatment, Complications, Prognosis & Natural History, Special Populations & Pregnancy
[46]
Shoag JE, Patel N, Posada L et al.. “Kidney Stones and Risk of Narcotic Use.” The Journal of urology (2019). PMID: 30829133 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
[47]
Tasian GE, Copelovitch L. “Evaluation and medical management of kidney stones in children.” The Journal of urology (2014). PMID: 24960469 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Complications, Prognosis & Natural History
[48]
Tasian GE, Kabarriti AE, Kalmus A et al.. “Kidney Stone Recurrence among Children and Adolescents.” The Journal of urology (2016). PMID: 27521691 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications, Special Populations & Pregnancy
[49]
Shoag J, Halpern J, Goldfarb DS et al.. “Risk of chronic and end stage kidney disease in patients with nephrolithiasis.” The Journal of urology (2014). PMID: 24929140 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors
[50]
Askeland EJ, Arlen AM, Erickson BA et al.. “Urological manifestations of Duchenne muscular dystrophy.” The Journal of urology (2013). PMID: 23357214 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors
[51]
Fankhauser CD, Kranzbühler B, Poyet C et al.. “Long-term Adverse Effects of Extracorporeal Shock-wave Lithotripsy for Nephrolithiasis and Ureterolithiasis: A Systematic Review.” Urology (2015). PMID: 25917723 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management: Medical vs Endourologic/Surgical
[52]
Shojaei-Zarghani S, Safarpour AR, Askari H et al.. “Metabolic Syndrome and Nephrolithiasis; A Cross Sectional Population-based Study on the Baseline Data of the PERSIAN Kavar Cohort Study.” Urology (2022). PMID: 36435345 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
[53]
Hsi RS, Kabagambe EK, Shu X et al.. “Race- and Sex-related Differences in Nephrolithiasis Risk Among Blacks and Whites in the Southern Community Cohort Study.” Urology (2018). PMID: 29753847 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
[54]
Huang MM, Winoker JS, Allaf ME et al.. “Evidence-based quality and accuracy of YouTube videos about nephrolithiasis.” BJU international (2020). PMID: 32805761 ↗
L5OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
[55]
Ganesan V, Chen WM, Jain R et al.. “Multiple sclerosis and nephrolithiasis: a matched-case comparative study.” BJU international (2017). PMID: 28220601 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment
[56]
Bagrodia A, Malcolm JB, Diblasio CJ et al.. “Variation in the incidence of and risk factors for the development of nephrolithiasis after radical or partial nephrectomy.” BJU international (2010). PMID: 20156212 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
[57]
Chung SD, Liu SP, Keller JJ et al.. “Urinary calculi and an increased risk of stroke: a population-based follow-up study.” BJU international (2012). PMID: 22583934 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
[58]
Lotan Y, Buendia Jiménez I, Lenoir-Wijnkoop I et al.. “Primary prevention of nephrolithiasis is cost-effective for a national healthcare system.” BJU international (2012). PMID: 22686216 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Special Populations & Pregnancy, Prevention, Screening & Surveillance
[59]
Eisner BH, Sheth S, Herrick B et al.. “The effects of ambient temperature, humidity and season of year on urine composition in patients with nephrolithiasis.” BJU international (2012). PMID: 22578009 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors
[60]
Alhefnawy MA, Selmy GI, Salah E et al.. “Mini-Percutaneous Nephrolithotomy vs Extracorporeal Shock Wave Lithotripsy for Management of Renal Stones in Pediatric Age Group Less Than 6 Years with Renal Stones Less Than 20 mm. A Prospective, Randomized Trial.” Journal of endourology (2026). PMID: 41814636 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Endoscopic & Procedural Technique Considerations, Complications, Prognosis & Natural History, Special Populations & Pregnancy
[61]
Ticinesi A, Nouvenne A, Ferraro PM et al.. “Idiopathic Calcium Nephrolithiasis and Hypovitaminosis D: A Case-control Study.” Urology (2015). PMID: 26494294 ↗
L3CASE_CONTROLCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
[62]
Kern A, Grimsby G, Mayo H et al.. “Medical and dietary interventions for preventing recurrent urinary stones in children.” The Cochrane database of systematic reviews (2017). PMID: 29117629 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management: Medical vs Endourologic/Surgical, Complications, Prognosis & Natural History, Prevention, Screening & Surveillance
[63]
Vosoughi F, Nikeghbali G, Yazdanmehr A et al.. “Lower Limb Fractures in Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis of Incidence, Biochemical Risk Factors, and Surgical Management.” Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2026). PMID: 42413661 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[64]
Yaseen T, Afzal MU, Alhamaidah MA et al.. “Pooled frequency of ceftriaxone-induced urolithiasis in pediatric patients: a systematic review and meta-analysis.” Pediatric nephrology (Berlin, Germany) (2026). PMID: 42262580 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Special Populations & Pregnancy
[65]
Villanueva-Congote J, Marin-Urrego JC, Bakbak H et al.. “Association Between Ambient Temperature and Urolithiasis: A Systematic Review and Meta-analysis.” Current urology reports (2026). PMID: 42176144 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute Management & Decompression
[66]
Kim SJ, Mock S, Stock JA. “Cystine nephrolithiasis.” Urology (2013). PMID: 23688378 ↗
L4CASE_REPORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Special Populations & Pregnancy
[67]
Li Z, Liu Y, Xu K et al.. “Association between oxidative balance score, genetic susceptibility and nephrolithiasis: a cohort study based on the UK Biobank.” European journal of nutrition (2026). PMID: 42371152 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors
[68]
Levin Iaina N, Elshami H, Asali M. “Risk Factors and Prediction of Acute Kidney Injury in Hospitalized Urology Patients: A Retrospective Cohort Study.” Journal of clinical medicine (2026). PMID: 42123226 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors
[69]
Kasabwala K, Borofsky M, Grove S et al.. “Association of stone surgery with patient-reported complications after spinal cord injury.” Neurourology and urodynamics (2022). PMID: 35114016 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Prevention, Screening & Surveillance
[70]
Sorokin I, Mamoulakis C, Miyazawa K et al.. “Epidemiology of stone disease across the world.” World journal of urology (2017). PMID: 28213860 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
[71]
De Coninck V, Keller EX, Somani B et al.. “Complications of ureteroscopy: a complete overview.” World journal of urology (2019). PMID: 31748953 ↗
L1REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute Management & Decompression, Long-term & Definitive Management: Medical vs Endourologic/Surgical
[72]
Canvasser NE, Alken P, Lipkin M et al.. “The economics of stone disease.” World journal of urology (2017). PMID: 28108799 ↗
L5OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute Management & Decompression
[73]
He H, Lei X, Zou X et al.. “Unravelling new mechanisms of occurrence and recurrence in calcium nephrolithiasis: the role of epigenetics.” World journal of urology (2026). PMID: 41944902 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
[74]
Wiseman O, Ventimiglia E, Doizi S et al.. “Effects of Silicone Hydrocoated Double Loop Ureteral Stent on Symptoms and Quality of Life in Patients Undergoing Flexible Ureteroscopy for Kidney Stone: A Randomized Multicenter Clinical Study.” The Journal of urology (2020). PMID: 32364838 ↗
L1RCTCited in: Clinical Presentation, Acute Management & Decompression
[75]
Sivalingam S, Streeper NM, Sehgal PD et al.. “Does Combination Therapy with Tamsulosin and Tolterodine Improve Ureteral Stent Discomfort Compared with Tamsulosin Alone? A Double-Blind, Randomized, Controlled Trial.” The Journal of urology (2015). PMID: 26393904 ↗
L1RCTCited in: Clinical Presentation
[76]
Wood LN, Markowitz MA, Parameshwar PS et al.. “Is it Safe to Reduce Water Intake in the Overactive Bladder Population? A Systematic Review.” The Journal of urology (2018). PMID: 29499207 ↗
L5SR_OBSCited in: Clinical Presentation, Complications, Prognosis & Natural History
[77]
Lovegrove CE, Geraghty RM, Yang B et al.. “Natural history of small asymptomatic kidney and residual stones over a long-term follow-up: systematic review over 25 years.” BJU international (2021). PMID: 34157218 ↗
L1SR_OBSCited in: Clinical Presentation, Diagnosis & Workup, Acute Management & Decompression, History and Evolution of Treatment, Prognosis & Natural History, Prevention, Screening & Surveillance
[78]
Syed JS, Khan A, Van-Ryn MG et al.. “Toradol to Reduce Ureteroscopy Symptoms Trial (TRUST).” Urology (2022). PMID: 35314184 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Endoscopic & Procedural Technique Considerations
[79]
Bhojani N, Wollin DA, El Tayeb MM et al.. “Prospective Multicenter Evaluation of Pain Before and After Removal of Nonobstructing Renal Calculi: A CoRE Initiative.” The Journal of urology (2023). PMID: 38100842 ↗
L2OTHERCited in: Clinical Presentation
[80]
Aksenov LI, Fairchild RJ, Kaplan SJ et al.. “Behavioral Economics in Urology: A Scoping Review.” The Journal of urology (2022). PMID: 35344397 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Complications
[81]
Haberal HB, Tonyali S, Piana A et al.. “Current Perspectives on Endourological Ex Vivo Stone Interventions in Kidney Transplantation: A Systematic Review.” Urology (2024). PMID: 38878828 ↗
L1SR_OBSCited in: Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, Prognosis & Natural History
[82]
Carvalho M, Martin RL, Passos RC et al.. “Nephrectomy as a cause of chronic kidney disease in the treatment of urolithiasis: a case-control study.” World journal of urology (2012). PMID: 22373698 ↗
L3CASE_CONTROLCited in: Clinical Presentation, Special Populations & Pregnancy
[83]
Umekawa T, Iguchi M, Uemura H et al.. “Oxalate ions and calcium oxalate crystal-induced up-regulation of osteopontin and monocyte chemoattractant protein-1 in renal fibroblasts.” BJU international (2006). PMID: 16925768 ↗
L5OTHERCited in: Clinical Presentation
[84]
Boonla C, Krieglstein K, Bovornpadungkitti S et al.. “Fibrosis and evidence for epithelial-mesenchymal transition in the kidneys of patients with staghorn calculi.” BJU international (2011). PMID: 21410631 ↗
L3OTHERCited in: Clinical Presentation, Severity, Staging & Risk Stratification
[85]
Weinberg AE, Hazard FK, Hsieh MH. “A case of genitourinary Crohn's disease.” Urology (2012). PMID: 22999453 ↗
L4CASE_REPORTCited in: Clinical Presentation
[86]
Cochran D, Cook G, Rensing A et al.. “A Rare Case of T-Cell Lymphoma Presenting With Bilateral Nephrolithiasis and Acute Renal Failure.” Urology (2020). PMID: 32592766 ↗
L4CASE_REPORTCited in: Clinical Presentation
[87]
Chang CP, Wang SS, Wen MC et al.. “Mucinous adenocarcinoma of the renal pelvis masquerading as xanthogranulomatous pyelonephritis.” Urology (2013). PMID: 23622771 ↗
L4CASE_REPORTCited in: Clinical Presentation
[88]
Acar B, Inci Arikan F, Emeksiz S et al.. “Risk factors for nephrolithiasis in children.” World journal of urology (2008). PMID: 18810456 ↗
L4OTHERCited in: Clinical Presentation
[89]
Martínez-Quintana E, Rodríguez-González F. “Crystalluria in adolescent and adult patients with congenital heart disease.” World journal of urology (2023). PMID: 37552266 ↗
L3OTHERCited in: Clinical Presentation
[90]
Giulioni C, Castellani D, Somani BK et al.. “The efficacy of retrograde intra-renal surgery (RIRS) for lower pole stones: results from 2946 patients.” World journal of urology (2023). PMID: 36930255 ↗
L4OTHERCited in: Clinical Presentation
[91]
Ortolini M, Breu B, Masnada A et al.. “Prolonged preoperative double J stenting increases post-ureteroscopy infectious complications.” World journal of urology (2025). PMID: 41160126 ↗
L3OTHERCited in: Clinical Presentation
[92]
Jahrreiss V, Yurdakul O, Veser J et al.. “Effect of parathyroidectomy on stone recurrence in primary hyperparathyroidism : A systematic review.” Wiener klinische Wochenschrift (2026). PMID: 41874646 ↗
L1SR_OBSCited in: Clinical Presentation, History and Evolution of Treatment
[93]
Hansen NF, Khizir L, Lay AH et al.. “Real-world efficacy and safety of the CVAC 2.0 ureteroscope: results from a single-center retrospective study.” Urolithiasis (2026). PMID: 42417984 ↗
L4COHORTCited in: Clinical Presentation
[94]
Manfredi G, Turisani A, Piasentier A et al.. “A Case of Tumor-Induced Osteomalacia Masked by Parathyroid Carcinoma.” Journal of clinical medicine (2026). PMID: 42279228 ↗
L4CASE_REPORTCited in: Clinical Presentation
[95]
Della Valentina S, Pierotti L, Sardella C et al.. “Clinical and genetic insights into Autosomal Dominant Hypocalcemia type 1: a single-center case series including genotype-phenotype correlations, pregnancy outcomes, and novel CASR variants.” Journal of endocrinological investigation (2026). PMID: 42223909 ↗
L4CASE_REPORTCited in: Clinical Presentation, Special Populations & Pregnancy
[96]
Bey A. “Primary hyperparathyroidism in pregnancy successfully treated with microwave ablation: a case report.” Frontiers in medicine (2026). PMID: 41657575 ↗
L4CASE_REPORTCited in: Clinical Presentation, Special Populations & Pregnancy
[97]
Eid MT, de Mul A, Muresan-Vintila L et al.. “Enamel renal syndrome due to FAM20A mutations: challenging kidney management in view of nephrocalcinosis, hypophosphatemia and hypocalciuria.” Orphanet journal of rare diseases (2026). PMID: 41645214 ↗
L4CASE_REPORTCited in: Clinical Presentation
[98]
De Coninck V, Keller EX, Rodríguez-Monsalve M et al.. “Systematic review of ureteral access sheaths: facts and myths.” BJU international (2018). PMID: 29752769 ↗
L5SR_OBSCited in: Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, Endoscopic & Procedural Technique Considerations
[99]
Dingwall A, Leighton J, Luk A et al.. “Ureteroscopy and lasertripsy for lower pole stones <2 cm, in situ vs displacement? A systematic review and meta-analysis.” BJU international (2024). PMID: 39400510 ↗
L1SR_OBSCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management: Medical vs Endourologic/Surgical, Endoscopic & Procedural Technique Considerations, Prognosis & Natural History
[100]
Wang HS, Panagides J, Cahill D et al.. “Dietary Risk Factors for Pediatric Kidney Stones: A Case-Control Study.” The Journal of urology (2022). PMID: 35377774 ↗
L3CASE_CONTROLCited in: Diagnosis & Workup, Special Populations & Pregnancy
[101]
Li Y, Yao Z, Zhou Z et al.. “Efficacy and safety of retrograde intrarenal surgery with a flexible and navigable suction sheath (FANS-RIRS) versus mini-percutaneous nephrolithotomy (mPCNL) for 2-3 cm renal stones: a systematic review and meta-analysis of randomized controlled trials.” World journal of urology (2026). PMID: 41817775 ↗
L1SR_MA_RCTCited in: Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, Prognosis & Natural History
[102]
Krajewski W, Nowak Ł, Tomczak W et al.. “Feasibility and safety of 6.3 Fr vs. 7.5 Fr digital disposable ureteroscopes in retrograde intrarenal surgery: a prospective randomised trial.” World journal of urology (2025). PMID: 40853384 ↗
L1RCTCited in: Diagnosis & Workup, History and Evolution of Treatment, Endoscopic & Procedural Technique Considerations, Complications
[103]
Saglam R, Muslumanoglu AY, Tokatlı Z et al.. “A new robot for flexible ureteroscopy: development and early clinical results (IDEAL stage 1-2b).” European urology (2014). PMID: 25059998 ↗
L4OTHERCited in: Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, Endoscopic & Procedural Technique Considerations, Prognosis & Natural History
[104]
Chen TT, Wang C, Ferrandino MN et al.. “Radiation Exposure during the Evaluation and Management of Nephrolithiasis.” The Journal of urology (2015). PMID: 26055822 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, Endoscopic & Procedural Technique Considerations
[105]
Torricelli FC, De SK, Gebreselassie S et al.. “Dyslipidemia and kidney stone risk.” The Journal of urology (2013). PMID: 24055417 ↗
L3OTHERCited in: Diagnosis & Workup
[106]
Ganesan V, De S, Greene D et al.. “Accuracy of ultrasonography for renal stone detection and size determination: is it good enough for management decisions?” BJU international (2016). PMID: 27459091 ↗
L3OTHERCited in: Diagnosis & Workup
[107]
Iremashvili V, Li S, Best SL et al.. “Clinical and demographic predictors of repeat stone surgery.” BJU international (2019). PMID: 31166648 ↗
L3OTHERCited in: Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Endoscopic & Procedural Technique Considerations, Complications, Prognosis & Natural History
[108]
Patel RM, Walia AS, Grohs E et al.. “Effect of positioning on ureteric stone retropulsion: 'gravity works'.” BJU international (2018). PMID: 30098120 ↗
L5OTHERCited in: Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, Endoscopic & Procedural Technique Considerations
[109]
Karim Z, Gérard B, Bakouh N et al.. “NHERF1 mutations and responsiveness of renal parathyroid hormone.” The New England journal of medicine (2008). PMID: 18784102 ↗
L3OTHERCited in: Diagnosis & Workup
[110]
Setthawong V, Srisubat A, Potisat S et al.. “Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal surgery (RIRS) for kidney stones.” The Cochrane database of systematic reviews (2023). PMID: 37526261 ↗
L1SR_OBSCited in: Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, Endoscopic & Procedural Technique Considerations, Prognosis & Natural History
[111]
Terro K, Vanthoor J, Wiseman O. “Evaluation of outcomes in kidney stone management: stone-free rate vs. cost vs. quality of life: a systematic review from EAU endourology.” World journal of urology (2026). PMID: 42001348 ↗
L1SR_OBSCited in: Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, Endoscopic & Procedural Technique Considerations, Prognosis & Natural History
[112]
Machado Filho C, Lepine HL, Lima MCMDS et al.. “One Session or Two? A Meta-Analysis of Same-Session Versus Staged Bilateral Percutaneous Nephrolithotomy.” Journal of endourology (2026). PMID: 41810589 ↗
L1SR_OBSCited in: Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, Complications, Prognosis & Natural History
[113]
Rapoport MJ, Sadah AY. “Gas-containing renal stones.” Urology (2006). PMID: 17070381 ↗
L4CASE_REPORTCited in: Diagnosis & Workup
[114]
Schulz AE, Green BW, Gupta K et al.. “Management of large kidney stones in the geriatric population.” World journal of urology (2023). PMID: 36856833 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, Prognosis & Natural History, Special Populations & Pregnancy
[115]
Kroczak T, Scotland KB, Chew B et al.. “Shockwave lithotripsy: techniques for improving outcomes.” World journal of urology (2017). PMID: 28608191 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Long-term & Definitive Management: Medical vs Endourologic/Surgical, Endoscopic & Procedural Technique Considerations
[116]
Patel RM, Jefferson FA, Owyong M et al.. “Characterization of intracalyceal pressure during ureteroscopy.” World journal of urology (2020). PMID: 32462302 ↗
L4OTHERCited in: Diagnosis & Workup
[117]
Sur RL, Krambeck AE, Large T et al.. “A Randomized Controlled Trial of Preoperative Prophylactic Antibiotics for Percutaneous Nephrolithotomy in Moderate to High Infectious Risk Population: A Report from the EDGE Consortium.” The Journal of urology (2020). PMID: 33369488 ↗
L1RCTCited in: Severity, Staging & Risk Stratification
[118]
Wong C, Xu P, Dean N et al.. “A prospective survey evaluating the visual quality of KARL STORZ fiberoptic, digital, and disposable flexible ureteroscopes.” World journal of urology (2025). PMID: 39937281 ↗
L1RCTCited in: Severity, Staging & Risk Stratification
[119]
La Rochelle JC, Coogan CL. “Urological manifestations of sarcoidosis.” The Journal of urology (2011). PMID: 22088341 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification
[120]
DeFoor W, Jackson E, Schulte M et al.. “Calcium-to-Citrate Ratio Distinguishes Solitary and Recurrent Urinary Stone Forming Children.” The Journal of urology (2017). PMID: 28365270 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification
[121]
Scheidt MJ, Hohenwalter EJ, Pinchot JW et al.. “ACR Appropriateness Criteria® Radiologic Management of Urinary Tract Obstruction.” Journal of the American College of Radiology : JACR (2020). PMID: 32370972 ↗
L5GUIDELINECited in: Severity, Staging & Risk Stratification
[122]
Dillman JR, Rigsby CK, Iyer RS et al.. “ACR Appropriateness Criteria® Hematuria-Child.” Journal of the American College of Radiology : JACR (2018). PMID: 29724430 ↗
L5GUIDELINECited in: Severity, Staging & Risk Stratification
[123]
Qaseem A, Dallas P, Forciea MA et al.. “Dietary and pharmacologic management to prevent recurrent nephrolithiasis in adults: a clinical practice guideline from the American College of Physicians.” Annals of internal medicine (2014). PMID: 25364887 ↗
L1GUIDELINECited in: Severity, Staging & Risk Stratification
[124]
Chappidi MR, Kates M, Tosoian JJ et al.. “Evaluation of gender-based disparities in time from initial haematuria presentation to upper tract urothelial carcinoma diagnosis: analysis of a nationwide insurance claims database.” BJU international (2017). PMID: 28418183 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification
[125]
Zieber L, Creiderman G, Krenawi M et al.. “A nomogram to predict "pure" vs. "mixed" uric acid urinary stones.” World journal of urology (2024). PMID: 39480595 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification
[126]
Bajaj M, Yuan L, Holmes LC et al.. “Predictors of surgical intervention following initial surveillance for acute ureteric colic.” World journal of urology (2018). PMID: 29600333 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification, Prevention, Screening & Surveillance
[127]
Golomb D, Confino I, Avda Y et al.. “Predictive value of family history of kidney stones for metabolic abnormalities and stone composition.” World journal of urology (2026). PMID: 42360497 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification
[128]
Reisiger K, Vardi I, Yan Y et al.. “Pediatric nephrolithiasis: does treatment affect renal growth?” Urology (2007). PMID: 17572213 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification, Prognosis & Natural History, Special Populations & Pregnancy
[129]
Assimos D, Krambeck A, Miller NL et al.. “Surgical Management of Stones: American Urological Association/Endourological Society Guideline, PART I.” The Journal of urology (2016). PMID: 27238616 ↗
L1GUIDELINECited in: Acute Management & Decompression, Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Special Populations & Pregnancy
[130]
Assimos D, Krambeck A, Miller NL et al.. “Surgical Management of Stones: American Urological Association/Endourological Society Guideline, PART II.” The Journal of urology (2016). PMID: 27238615 ↗
L1GUIDELINECited in: Acute Management & Decompression, History and Evolution of Treatment, Special Populations & Pregnancy
[131]
Metzler IS, Smith-Bindman R, Moghadassi M et al.. “Emergency Department Imaging Modality Effect on Surgical Management of Nephrolithiasis: A Multicenter, Randomized Clinical Trial.” The Journal of urology (2016). PMID: 27773846 ↗
L1RCTCited in: Acute Management & Decompression
[132]
Demasi M, Segall M, Mengotto A et al.. “Optimizing pain management following kidney stone surgery: can we avoid narcotics?” World journal of urology (2022). PMID: 36371742 ↗
L1RCTCited in: Acute Management & Decompression, History and Evolution of Treatment
[133]
Barghouthy Y, Wiseman O, Ventimiglia E et al.. “Silicone-hydrocoated ureteral stents encrustation and biofilm formation after 3-week dwell time: results of a prospective randomized multicenter clinical study.” World journal of urology (2021). PMID: 33688992 ↗
L1RCTCited in: Acute Management & Decompression
[134]
Alexander CE, Gowland S, Cadwallader J et al.. “Shock wave lithotripsy (SWL): outcomes from a national SWL database in New Zealand.” BJU international (2016). PMID: 26923107 ↗
L2OTHERCited in: Acute Management & Decompression
[135]
Berger I, Wildhofen S, Lee A et al.. “Emergency nephrectomy due to severe urosepsis: a retrospective, multicentre analysis of 65 cases.” BJU international (2009). PMID: 19338556 ↗
L4OTHERCited in: Acute Management & Decompression
[136]
Asher GN, Viprakasit DP, Aymes SE et al.. “Prevention of Recurrent Nephrolithiasis in Adults and Children : A Systematic Review.” Annals of internal medicine (2026). PMID: 41871357 ↗
L1SR_OBSCited in: Acute Management & Decompression, Complications, Prognosis & Natural History, Prevention, Screening & Surveillance
[137]
Balen F, Cideron C, Noizet M et al.. “Predicting surgery within one week of emergency department presentation for renal colic using the CLAD-MB score: A prospective cohort study.” The American journal of emergency medicine (2025). PMID: 41175442 ↗
L2COHORTCited in: Acute Management & Decompression, History and Evolution of Treatment
[138]
Wollin DA, Joyce AD, Gupta M et al.. “Antibiotic use and the prevention and management of infectious complications in stone disease.” World journal of urology (2017). PMID: 28160088 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Decompression
[139]
Eredics K, Drerup M, Özsoy M et al.. “Active stone removal is a safe option for ocotogenarians and nonagenarians with nephrolithiasis.” World journal of urology (2023). PMID: 36754879 ↗
L3OTHERCited in: Acute Management & Decompression
[140]
Ansari MI, Khan SA, Thakur DK et al.. “Comparative efficacy of pre-stented versus non-stented retrograde intrarenal surgery: A randomized controlled trial.” Medicine (2025). PMID: 40441236 ↗
L1RCTCited in: Acute Management & Decompression
[141]
Dai JC, Nicholson TM, Chang HC et al.. “Nephrolithiasis in Pregnancy: Treating for Two.” Urology (2020). PMID: 32866511 ↗
L5REVIEW_NARRATIVECited in: Acute Management & Decompression, Special Populations & Pregnancy
[142]
Roth JD, Pariser JJ, Stout TE et al.. “Presentation and Management Patterns of Lower Urinary Tract Symptoms in Adults Due to Rare Inherited Neuromuscular Diseases.” Urology (2019). PMID: 31626855 ↗
L4REVIEW_NARRATIVECited in: Acute Management & Decompression, Complications, Prognosis & Natural History
[143]
Raskolnikov D, Hall MK, Ngo SD et al.. “Strategies to Optimize Nephrolithiasis Emergency Care (STONE): Prospective Evaluation of an Emergency Department Clinical Pathway.” Urology (2021). PMID: 34757049 ↗
L2OTHERCited in: Acute Management & Decompression
[144]
Hsiang WR, Yousman L, Kim D et al.. “Access to Urologic Care at Urgent Care Centers.” Urology (2021). PMID: 34181971 ↗
L2OTHERCited in: Acute Management & Decompression, Endoscopic & Procedural Technique Considerations
[145]
DeWitt-Foy ME, Gao T, Schold J et al.. “Stones and Moans: Higher Number of Nephrolithiasis Related Encounters Increases the Odds of Opioid Misuse.” Urology (2021). PMID: 34653430 ↗
L3OTHERCited in: Acute Management & Decompression
[146]
Ziemba JB, Jones A, Lin G et al.. “Postoperative Recovery of Quality-of-Life Following Ureteroscopy for Nephrolithiasis: The Impact on Pain Intensity and Interference and the Ability to Participate in Social Roles.” Urology (2024). PMID: 38508532 ↗
L2OTHERCited in: Acute Management & Decompression
[147]
Lyon M, Sun A, Shah A et al.. “Comparison of Radiation Exposure for Pregnant Patients Requiring Intervention for Suspected Obstructing Nephrolithiasis.” Urology (2023). PMID: 37783398 ↗
L3OTHERCited in: Acute Management & Decompression, Special Populations & Pregnancy
[148]
Dean NS, Millan B, Uy M et al.. “Ureteral Wall Thickness Is an Effective Predictor of Ureteral Stone Impaction and Management Outcomes: A Systematic Review and Meta-analysis.” The Journal of urology (2023). PMID: 37232694 ↗
L1SR_OBSCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, Prognosis & Natural History
[149]
Leder BZ, Tsai JN, Uihlein AV et al.. “Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.” Lancet (London, England) (2015). PMID: 26144908 ↗
L1RCTCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment
[150]
Baldea KG, Patel PM, Delos Santos G et al.. “Paravertebral block for percutaneous nephrolithotomy: a prospective, randomized, double-blind placebo-controlled study.” World journal of urology (2020). PMID: 31982963 ↗
L1RCTCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical
[151]
Higazy A, Kandil M, Elshafei A et al.. “Flexible mini-percutaneous nephrolithotomy versus retrograde intra-renal surgery in the management of renal stones: a randomized controlled trial.” World journal of urology (2025). PMID: 40418257 ↗
L1RCTCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Endoscopic & Procedural Technique Considerations, Prognosis & Natural History
[152]
El-Shaer W, Kandeel W, Abdel-Lateef S et al.. “Complete Ultrasound-guided Percutaneous Nephrolithotomy in Prone and Supine Positions: A Randomized Controlled Study.” Urology (2019). PMID: 30902696 ↗
L1RCTCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment
[153]
Davis NF, Quinlan MR, Poyet C et al.. “Miniaturised percutaneous nephrolithotomy versus flexible ureteropyeloscopy: a systematic review and meta-analysis comparing clinical efficacy and safety profile.” World journal of urology (2018). PMID: 29450733 ↗
L1SR_OBSCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, Endoscopic & Procedural Technique Considerations, Prognosis & Natural History
[154]
Talyshinskii A, Juliebø-Jones P, Tzelves L et al.. “Current state of AI for shockwave lithotripsy: a systematic review from YAU and EAU endourology.” World journal of urology (2025). PMID: 40643681 ↗
L5SR_OBSCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical
[155]
Zilberman DE, Lipkin ME, de la Rosette JJ et al.. “Tubeless percutaneous nephrolithotomy--the new standard of care?” The Journal of urology (2010). PMID: 20723920 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, Endoscopic & Procedural Technique Considerations
[156]
DiBianco JM, Daignault-Newton S, Fernandez Moncaleano G et al.. “Ureteroscopy vs Shock Wave Lithotripsy for Lower Pole Renal Stones: Treatment Variation and Outcomes in a Surgical Collaborative.” The Journal of urology (2025). PMID: 40489579 ↗
L2OTHERCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical
[157]
Bloom J, Matthews G, Phillips J. “Factors Influencing Readmission after Elective Ureteroscopy.” The Journal of urology (2015). PMID: 26602889 ↗
L4OTHERCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Endoscopic & Procedural Technique Considerations
[158]
Smaldone MC, Corcoran AT, Docimo SG et al.. “Endourological management of pediatric stone disease: present status.” The Journal of urology (2008). PMID: 19012920 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, Endoscopic & Procedural Technique Considerations
[159]
Ziemba JB, Matlaga BR. “Guideline of guidelines: kidney stones.” BJU international (2015). PMID: 25684222 ↗
L1OTHERCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, Complications, Prognosis & Natural History
[160]
Ganpule A, Chhabra JS, Kore V et al.. “Factors predicting outcomes of micropercutaneous nephrolithotomy: results from a large single-centre experience.” BJU international (2015). PMID: 26331966 ↗
L4OTHERCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, Endoscopic & Procedural Technique Considerations
[161]
Randell RL, Maharaj A, Laughon M et al.. “Population Pharmacokinetics and Exposure-Safety Analysis of Furosemide in Preterm Infants.” Journal of clinical pharmacology (2026). PMID: 42003090 ↗
L2RCTCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Special Populations & Pregnancy
[162]
Talyshinskii A, Khairley G, Tur AB et al.. “Role of pediatric ureteroscopy for large renal stones: a systematic review and meta-analysis from EAU endourology.” World journal of urology (2025). PMID: 41176750 ↗
L1SR_OBSCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, Complications, Special Populations & Pregnancy
[163]
Jung M, Rai A, Wang L et al.. “Nephrolithiasis in a 17-Year-Old Male With Seckel Syndrome and Horseshoe Kidneys: Case Report and Review of the Literature.” Urology (2018). PMID: 29894776 ↗
L4CASE_REPORTCited in: Long-term & Definitive Management: Medical vs Endourologic/Surgical, History and Evolution of Treatment, Endoscopic & Procedural Technique Considerations
[164]
Pearle MS, Goldfarb DS, Assimos DG et al.. “Medical management of kidney stones: AUA guideline.” The Journal of urology (2014). PMID: 24857648 ↗
L1GUIDELINECited in: History and Evolution of Treatment, Complications, Prognosis & Natural History
[165]
Fink HA, Akornor JW, Garimella PS et al.. “Diet, fluid, or supplements for secondary prevention of nephrolithiasis: a systematic review and meta-analysis of randomized trials.” European urology (2009). PMID: 19321253 ↗
L1SR_OBSCited in: History and Evolution of Treatment, Complications, Prognosis & Natural History, Prevention, Screening & Surveillance
[166]
Brain E, Geraghty RM, Lovegrove CE et al.. “Natural History of Post-Treatment Kidney Stone Fragments: A Systematic Review and Meta-Analysis.” The Journal of urology (2021). PMID: 33904756 ↗
L1SR_OBSCited in: History and Evolution of Treatment, Prognosis & Natural History
[167]
Williams JJ, Rodman JS, Peterson CM. “A randomized double-blind study of acetohydroxamic acid in struvite nephrolithiasis.” The New England journal of medicine (1984). PMID: 6472365 ↗
L1RCTCited in: History and Evolution of Treatment
[168]
Lu P, Chen K, Wang Z et al.. “Clinical efficacy and safety of flexible ureteroscopic lithotripsy using 365 μm holmium laser for nephrolithiasis: a prospective, randomized, controlled trial.” World journal of urology (2019). PMID: 31030229 ↗
L1RCTCited in: History and Evolution of Treatment
[169]
Ozkaya O, Söylemezoğlu O, Misirlioğlu M et al.. “Polymorphisms in the vitamin D receptor gene and the risk of calcium nephrolithiasis in children.” European urology (2003). PMID: 12814692 ↗
L3OTHERCited in: History and Evolution of Treatment
[170]
Pagano F, Tasca A, Oliva G. “The evolution of renal function after surgical treatment of malignant lithiasis with severely compromised renal function.” European urology (1982). PMID: 7060603 ↗
L4OTHERCited in: History and Evolution of Treatment
[171]
Donsimoni R, Hennequin C, Fellahi S et al.. “New aspects of urolithiasis in France. GERBAP: Groupe d'Evaluation et de Recherche des Biologistes de l'Assistance Publique des Hôpitaux de Paris.” European urology (1997). PMID: 9032529 ↗
L2OTHERCited in: History and Evolution of Treatment
[172]
Taylor EN, Chan AT, Giovannucci EL et al.. “Cholelithiasis and the risk of nephrolithiasis.” The Journal of urology (2011). PMID: 21944091 ↗
L2OTHERCited in: History and Evolution of Treatment
[173]
Krautschick A, Esen T. “The role of the papilla in idiopathic calcium oxalate nephrolithiasis.” World journal of urology (1997). PMID: 9280049 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[174]
Srirangapatanam S, Wiener S, Stoller ML. “Role of core body temperature in nephrolithiasis.” BJU international (2020). PMID: 32750202 ↗
L3OTHERCited in: History and Evolution of Treatment
[175]
Parr JM, Desai D, Winkle D. “Natural history and quality of life in patients with cystine urolithiasis: a single centre study.” BJU international (2015). PMID: 26204884 ↗
L4OTHERCited in: History and Evolution of Treatment
[176]
Penniston KL, Jones AN, Nakada SY et al.. “Vitamin D repletion does not alter urinary calcium excretion in healthy postmenopausal women.” BJU international (2009). PMID: 19389005 ↗
L2OTHERCited in: History and Evolution of Treatment
[177]
Baggio B, Gambaro G, Marchini F et al.. “An inheritable anomaly of red-cell oxalate transport in "primary" calcium nephrolithiasis correctable with diuretics.” The New England journal of medicine (1986). PMID: 3945245 ↗
L3OTHERCited in: History and Evolution of Treatment
[178]
Husmann DA, Pappas TN, Preminger GM. “Nephrolithiasis on the National Stage: The Kidney Stones of President Lyndon B. Johnson.” Urology (2024). PMID: 39293672 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Endoscopic & Procedural Technique Considerations
[179]
Bhan A, Simon R, Yaseen A et al.. “The predictive value of 24-hour urinary calcium for kidney stone risk in primary hyperparathyroidism: insight from a retrospective study of parathyroid adenoma cases.” Frontiers in endocrinology (2025). PMID: 41377934 ↗
L3COHORTCited in: History and Evolution of Treatment
[180]
Lieske JC, Groothoff JW, Frishberg Y et al.. “Natural History of Advanced Primary Hyperoxaluria Type 1: A Retrospective Study.” Kidney medicine (2025). PMID: 41209157 ↗
L3COHORTCited in: History and Evolution of Treatment
[181]
Qi H, Chen H, Dalbeth N et al.. “Two-decade trajectories of gout: a multicentre cohort study of 10 658 Chinese patients with gout.” Rheumatology (Oxford, England) (2026). PMID: 41137675 ↗
L2COHORTCited in: History and Evolution of Treatment
[182]
Liu N, Feng Y, Li J et al.. “Relationship between the dietary inflammatory index and kidney stone prevalence.” World journal of urology (2022). PMID: 35396944 ↗
L2OTHERCited in: History and Evolution of Treatment
[183]
Green BW, Labagnara K, Macdonald E et al.. “Evaluating the association between food insecurity and risk of nephrolithiasis: an analysis of the National Health and Nutrition Examination Survey.” World journal of urology (2022). PMID: 36125503 ↗
L2OTHERCited in: History and Evolution of Treatment
[184]
Ricapito A, Gupta K, Zipkin J et al.. “Comparison of metabolic parameters between pure-uric acid and mixed-uric acid kidney stone formers.” World journal of urology (2024). PMID: 38478092 ↗
L3OTHERCited in: History and Evolution of Treatment
[185]
Cotta BH, Nguyen V, Sur RL et al.. “Opiates prescribed for acute renal colic are associated with prolonged use.” World journal of urology (2020). PMID: 32740804 ↗
L3OTHERCited in: History and Evolution of Treatment
[186]
Liu CJ, Li WH, Li CH et al.. “Nephrolithiasis is associated with the severity of coronary artery calcification, but not with coronary artery stenosis.” World journal of urology (2023). PMID: 37284843 ↗
L3OTHERCited in: History and Evolution of Treatment
[187]
Gridley CM, Sourial MW, Lehman A et al.. “Medical dissolution therapy for the treatment of uric acid nephrolithiasis.” World journal of urology (2019). PMID: 30810833 ↗
L4OTHERCited in: History and Evolution of Treatment
[188]
Ganesan C, Frassetto L, Pao AC. “Nephrolithiasis: A Paleolithic Perspective and Physiological Approach to Prevention.” Annual review of medicine (2026). PMID: 41592925 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[189]
Bacchetta J, Acquaviva-Bourdain C, Abid N et al.. “Primary hyperoxaluria(s): from trials to real-life data and pipeline therapies.” Kidney international (2026). PMID: 41579959 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[190]
Abukhalil M, Mehjez O, Aladdam M et al.. “The radiological evaluation process of the potential live kidney donor assessment programme at al-Shifa Hospital: study and clinical audit.” Lancet (London, England) (2018). PMID: 29553430 ↗
L4OTHERCited in: Endoscopic & Procedural Technique Considerations
[191]
Moon H, Kim YC, Park HC et al.. “Association between nephrolithiasis and kidney disease progression in patients with autosomal dominant polycystic kidney disease: a prospective cohort study.” Clinical kidney journal (2026). PMID: 42428517 ↗
L2COHORTCited in: Endoscopic & Procedural Technique Considerations
[192]
Wymer KM, Boddu SP, Choudry M et al.. “Access to Care and Health Care Utilization Among Patients With Nephrolithiasis.” Urology (2024). PMID: 38432429 ↗
L3OTHERCited in: Endoscopic & Procedural Technique Considerations
[193]
Burns ZR, Sawyer KN, Selph JP. “Appendiceal Interposition for Ureteral Stricture Disease: Technique and Surgical Outcomes.” Urology (2020). PMID: 32961223 ↗
L4OTHERCited in: Endoscopic & Procedural Technique Considerations, Complications
[194]
Miernik A, Wilhelm K, Ardelt PU et al.. “Standardized flexible ureteroscopic technique to improve stone-free rates.” Urology (2012). PMID: 23206763 ↗
L4OTHERCited in: Endoscopic & Procedural Technique Considerations
[195]
Oliveira AV, Sampaio ALN, Mascarenhas RW et al.. “Thiazide and thiazide-like diuretics for kidney stones recurrence: a systematic review and network meta-analysis of randomised controlled trials.” World journal of urology (2025). PMID: 41396435 ↗
L1SR_MA_RCTCited in: Complications, Prognosis & Natural History, Prevention, Screening & Surveillance
[196]
Andrade MA, Godinho NJS, de Amorim LGCR et al.. “Single-session bilateral vs. staged unilateral renal stone removal: comparative outcomes in a systematic review and meta-analysis.” World journal of urology (2025). PMID: 41021030 ↗
L1SR_OBSCited in: Complications
[197]
Garbens A, Pearle MS. “Causes and prevention of kidney stones: separating myth from fact.” BJU international (2021). PMID: 34192414 ↗
L5REVIEW_NARRATIVECited in: Complications, Prognosis & Natural History
[198]
Worcester EM, Coe FL, Evan AP et al.. “Reduced renal function and benefits of treatment in cystinuria vs other forms of nephrolithiasis.” BJU international (2006). PMID: 16686727 ↗
L3OTHERCited in: Complications
[199]
Yang JYC, Sarwal RD, Ky K et al.. “Non-radiological assessment of kidney stones using the kidney injury test (KIT), a spot urine assay.” BJU international (2020). PMID: 31869527 ↗
L3OTHERCited in: Complications
[200]
Sui W, Yang H, Velasquez MC et al.. “Re-defining the interpretation of 24-h urine studies for stone formers.” BJU international (2025). PMID: 39846125 ↗
L3OTHERCited in: Complications
[201]
Freise J, Nunez M, Chi T et al.. “Therapeutic Living Donor Nephrectomy for Proximal Ureteral Pathology: A Longitudinal Case Series.” Urology (2022). PMID: 35550384 ↗
L4CASE_REPORTCited in: Complications, Prognosis & Natural History
[202]
Svihra J, Sopilko I, Blichova T et al.. “The comparison of synchronous bilateral and unilateral percutaneous nephrolithotomy: Meta-analysis.” Central European journal of urology (2026). PMID: 42375725 ↗
L1SR_OBSCited in: Complications
[203]
Sui W, Hancock J, Asplin JR et al.. “Nephrolithiasis and Elevated Urinary Ammonium: A Matched Comparative Study.” Urology (2020). PMID: 32544550 ↗
L3OTHERCited in: Complications, Prognosis & Natural History
[204]
Turner EN, Talwar R, Familusi OO et al.. “Race/Ethnicity and Insurance's Impact on Delays to Kidney Stone Surgery Scheduling.” Urology (2022). PMID: 35469809 ↗
L3OTHERCited in: Complications
[205]
Anderson A, Singh JA. “Pegloticase for chronic gout.” The Cochrane database of systematic reviews (2010). PMID: 20238366 ↗
L1SR_OBSCited in: Prognosis & Natural History
[206]
Bjelakovic G, Gluud LL, Nikolova D et al.. “Vitamin D supplementation for prevention of mortality in adults.” The Cochrane database of systematic reviews (2011). PMID: 21735411 ↗
L1SR_OBSCited in: Prognosis & Natural History, Special Populations & Pregnancy
[207]
Bjelakovic G, Gluud LL, Nikolova D et al.. “Vitamin D supplementation for prevention of cancer in adults.” The Cochrane database of systematic reviews (2014). PMID: 24953955 ↗
L1SR_OBSCited in: Prognosis & Natural History, Special Populations & Pregnancy
[208]
Bjelakovic G, Gluud LL, Nikolova D et al.. “Vitamin D supplementation for prevention of mortality in adults.” The Cochrane database of systematic reviews (2014). PMID: 24414552 ↗
L1SR_OBSCited in: Prognosis & Natural History, Special Populations & Pregnancy
[209]
Bevill M, Kattula A, Cooper CS et al.. “The Modern Metabolic Stone Evaluation in Children.” Urology (2016). PMID: 27838366 ↗
L4OTHERCited in: Prognosis & Natural History, Special Populations & Pregnancy
[210]
Simsekoglu MF, Ozman O, Sahin MF et al.. “Outcomes of retrograde intrarenal surgery in patients on anticoagulant or antiplatelet therapy: a multicenter matched case-control study by the RIRSearch Study Group.” World journal of urology (2025). PMID: 41148357 ↗
L3CASE_CONTROLCited in: Special Populations & Pregnancy
[211]
Tong CMC, Bicknell BT, Ellison JS et al.. “Influence of a Prospective Multicenter Clinical Trial on Adherence to Imaging Acquisition and Office Visit Follow-Up After Kidney Stone Surgery: A Bi-Institutional Experience.” Journal of endourology (2026). PMID: 42051168 ↗
L3TRIAL_NONRANDOMCited in: Special Populations & Pregnancy
[212]
Jha V, Venkateswarlu M, Shaharyar A et al.. “Thiazide therapy in chronic hypoparathyroidism: effects on hypercalciuria and renal function-a systematic review and exploratory meta-analysis.” Journal of endocrinological investigation (2026). PMID: 42287530 ↗
L1SR_OBSCited in: Special Populations & Pregnancy
[213]
Mazumder H, Gain EP, Shimul MH et al.. “Ambient Temperature and Risk of Renal Colic: A Systematic Review and Meta-analysis.” Kidney medicine (2025). PMID: 41531667 ↗
L2SR_OBSCited in: Special Populations & Pregnancy
[214]
Rosenberg E, Sergienko R, Abu-Ghanem S et al.. “Nephrolithiasis during pregnancy: characteristics, complications, and pregnancy outcome.” World journal of urology (2011). PMID: 21691721 ↗
L3OTHERCited in: Special Populations & Pregnancy
[215]
Khargi R, Blake RM, Yaghoubian AJ et al.. “Drivers of calcium oxalate stone formation in the octogenarian population.” World journal of urology (2023). PMID: 37847263 ↗
L4OTHERCited in: Special Populations & Pregnancy
[216]
Lee AS, McGarry L, Bowen DK et al.. “Patient Characteristics Associated With Completion of 24-hour Urine Analyses Among Children and Adolescents With Nephrolithiasis.” Urology (2019). PMID: 30796989 ↗
L2OTHERCited in: Special Populations & Pregnancy
[217]
Abedali ZA, Large T, Heiman JM et al.. “Percutaneous Nephrolithotomy in the 80 Years of Age and Older Population.” Urology (2019). PMID: 31536740 ↗
L3OTHERCited in: Special Populations & Pregnancy
[218]
Lotan Y, Pearle MS. “Cost-effectiveness of primary prevention strategies for nephrolithiasis.” The Journal of urology (2011). PMID: 21683379 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[219]
Milose JC, Kaufman SR, Hollenbeck BK et al.. “Prevalence of 24-hour urine collection in high risk stone formers.” The Journal of urology (2013). PMID: 24018242 ↗
L2OTHERCited in: Prevention, Screening & Surveillance
[220]
Veronese N, Ciriminna S, Errera CM et al.. “Preventing and treating kidney stones: an umbrella review of meta-analyses of non-surgical randomized controlled trials.” Minerva urology and nephrology (2025). PMID: 40891477 ↗
L1SR_MA_RCTCited in: Prevention, Screening & Surveillance
[221]
Porto BC, Terada BD, Gonçalves FG et al.. “Thiazide diuretics for preventing calcium oxalate recurrent kidney stones: an updated systematic review, meta-analysis and trial sequential analysis of randomized controlled trials.” Minerva urology and nephrology (2025). PMID: 40528770 ↗
L1SR_MA_RCTCited in: Prevention, Screening & Surveillance
[222]
Boissier R, Rodriguez-Faba O, Zakri RH et al.. “Evaluation of the Effectiveness of Interventions on Nephrolithiasis in Transplanted Kidney.” European urology focus (2022). PMID: 36567234 ↗
L1SR_OBSCited in: Prevention, Screening & Surveillance
[223]
Anagnostis P, Vaitsi K, Veneti S et al.. “Efficacy of parathyroidectomy compared with active surveillance in patients with mild asymptomatic primary hyperparathyroidism: a systematic review and meta-analysis of randomized-controlled studies.” Journal of endocrinological investigation (2020). PMID: 33074457 ↗
L1SR_OBSCited in: Prevention, Screening & Surveillance
[224]
Sui W, Gupta L, Azzawi AS et al.. “The association between quality of life, intensity of counseling and health literacy amongst patients with nephrolithiasis.” World journal of urology (2026). PMID: 41843185 ↗
L4OTHERCited in: Prevention, Screening & Surveillance
[225]
Patel SR, Wells S, Ruma J et al.. “Automated volumetric assessment by noncontrast computed tomography in the surveillance of nephrolithiasis.” Urology (2012). PMID: 22578829 ↗
L3OTHERCited in: Prevention, Screening & Surveillance
[226]
Bernard J, Song L, Henderson B et al.. “Association Between Daily Water Intake and 24-hour Urine Volume Among Adolescents With Kidney Stones.” Urology (2020). PMID: 32004558 ↗
L4OTHERCited in: Prevention, Screening & Surveillance

Quick Reference

Overview and Recommendations

Background

Evaluation

Management

Board Review — High Yield

Deep Dive — Evidence Details

Definition, Classification & Nomenclature

Synonyms and Abbreviations

Classification Systems

Clinical Significance and Terminology

Pathophysiology & Mechanism

The Physicochemical Cascade

Randall's Plaque and Interstitial Mechanisms

Cellular and Molecular Mediators

Obstructive Physiology and Pressure Dynamics

Metabolic and Secondary Drivers

Epidemiology, Etiology & Risk Factors

Metabolic and Systemic Risk Factors

Environmental and Seasonal Drivers

Genetic and Anatomical Etiologies

Risk Factor Summary Table

Clinical Presentation

Presenting Symptoms

Physical Examination and Red Flags

Phenotypic Variants and Special Populations

Post-Procedural Symptoms

Diagnosis & Workup

History and Physical

Imaging Modalities

Laboratory Studies

Diagnostic Algorithm

Controversies and Guideline Disagreement

Severity, Staging & Risk Stratification

Clinical and Stone-Related Predictors of Intervention

Metabolic and Genetic Risk Stratification

Anatomical and Surgical Risk Tiers

Infectious Risk Stratification

Acute Management & Decompression

Step 1: Initial Assessment and Triage

Step 2: Emergency Decompression

Step 3: Acute Pain Management

Step 4: Medical Expulsive Therapy (MET)

Step 5: Transition to Definitive Management

Controversies and Guideline Disagreement

Long-term & Definitive Management: Medical vs Endourologic/Surgical

Step 1: Surveillance and Medical Prevention

Step 2: Selection of Surgical Modality

Step 3: Optimization of Endourologic Outcomes

Step 4: Perioperative Pain and Safety

Controversies and Guideline Disagreement

History and Evolution of Treatment

The Rise of Minimally Invasive Surgery

Evolution of Medical Expulsive Therapy (MET)

Landmark Trials in Metabolic Prevention

Controversies and Guideline Disagreement

Endoscopic & Procedural Technique Considerations

Ureteroscopy and Retrograde Intrarenal Surgery (RIRS)

Percutaneous Nephrolithotomy (PCNL) and Miniaturization

Intraoperative Optimization and Safety

Comparative Outcomes by Modality

Special Anatomical Considerations

Complications

Procedural and Surgical Complications

Medical and Metabolic Complications

Long-term Sequelae and Recurrence

Complication Summary Table

Prognosis & Natural History

Recurrence and Surgical Re-intervention

Natural History of Asymptomatic and Residual Stones

Long-term Functional Outcomes

Impact of Prophylaxis on Recurrence

Special Populations & Pregnancy

Pregnancy

Pediatrics

Geriatric Patients

Anticoagulated Patients

Controversies and Guideline Disagreement

Prevention, Screening & Surveillance

Step 3: Acute Pain